

RECEIVED

OCT 30 2000

TECH CENTER 1600/2800

R.H. 10  
#18  
11/1/00

*Cell - Cycle Regulatory Proteins,  
Antibodies and Uses Related Thereto*  
~~CYCLIN COMPLEX REARRANGEMENTS~~  
~~AND USES RELATED THERETO~~

*Related Applications*

This application claims priority to Patent Cooperation Treaty Application No. PCT US 93/09945 entitled "Cyclin Complex Rearrangements and Uses Related Thereto" and is a continuation-in-part of U.S.S.N. Serial Number 07/991,997 filed December 17, 1992 and entitled "Cyclin Complex Rearrangements and Uses Related Thereto" which is a continuation-in-part of U.S.S.N. Serial Number 07/963,308 filed October 16, 1992 and entitled "D-Type Cyclin and Uses Related Thereto" which is a continuation-in-part of U.S.S.N. Serial Number 07/888,178 filed May 26, 1992 and entitled "D-Type Cyclin and Uses Related Thereto", which corresponds to and claims priority to Patent Cooperation Treaty Application No. PCT/US92/04146, filed May 18, 1992 and entitled "D-Type Cyclin and Uses Related Thereto", and to U.S.S.N. 07/701,514, filed May 16, 1991 and entitled "D-Type Cyclin and Uses Related Thereto." The teachings of U.S.S.N. 07/991,997, 07/963,308, 07/888,178, 07/701,514 and the PCT Applications are incorporated herein by reference.

*Funding*

Work described herein was supported by National Institutes of Health Grant and the Howard Hughes Medical Institute. The United States Government has certain rights in the invention.

*Background of the Invention*

Neoplasia is characterized by deregulated cell growth and division. Inevitably, molecular pathways controlling cell growth must interact with those regulating cell division. It was not until very recently, however, that experimental evidence became available to bring such connection to light. Cyclin A was found in association with the adenovirus oncoprotein E1A in virally transformed cells (Giordona et al. *Cell* 58:981 (1989); and Pines et al. *Nature* 346:760 (1990)). In an early hepatocellular carcinoma, the human cyclin A gene was found to be the integration site of a fragment of the hepatitis B virus, which leads to activation of cyclin A transcription and a chimeric viral cyclin A protein that is not degradable *in vitro* (Wang et al. *Nature* 343:555 (1990)). The cell cycle gene implicated most strongly in oncogenesis thus far is the human cyclin D1. It was originally isolated through genetic

complementation of yeast G<sub>1</sub> cyclin deficient strains (Xiong et al. *Cell* 65:691(1991); and Lew et al. *Cell* 66:1197 (1991)), as cellular genes whose transcription is stimulated by CSF-1 in murine macrophages (Matsushine et al. *Cell* 65:701 (1991)) and in the putative oncogene *PRAD1* rearranged in parathyroid tumors (Montokura et al. *Nature* 350:512 (1991)). Two  
5 additional human D-type cyclins, cyclins D2 and D3, were subsequently identified using PCR and low-stringency hybridization techniques (Inaba et al. *Genomics* 13:565 (1992); and Xiong et al. *Genomics* 13:575 (1992)). Cyclin D1 is genetically linked to the *bcl-1* oncogene, a locus activated by translocation to an immunoglobulin gene enhancer in some B-cell lymphomas and leukemias, and located at a site of gene amplification in 15-20% of human  
10 breast cancers and 25-48% of squamous cell cancers of head and neck origin.

Cyclins are proteins that were discovered due to their intense synthesis following the fertilization of marine invertebrate eggs (Rosenthal, E.T. et al., *Cell* 20:487-494 (1980)). It was subsequently observed that the abundance of two types of cyclin, A and B, oscillated during the early cleavage divisions due to abrupt proteolytic degradation of the polypeptides  
15 at mitosis and thus, they derived their name (Evans, T. et al., *Cell* 33:389-396 (1983); Swenson, K.I. et al., *Cell* 47:867-870 (1986); Standart, N. et al., *Dev. Biol.* 124:248-258 (1987)). Subsequently, cyclin genes have been isolated from virtually all eukaryotic species and constitute a multigene family (for review, see Xiong et al. *Curr Biology* 1:362 (1991)).

Active rather than passive involvement of cyclins in regulation of cell division  
20 became apparent with the observation that a clam cyclin mRNA could cause activation of frog oocytes and entry of these cells into M phase (Swenson, K.I. et al., *Cell* 7:867-870 (1986)). Activation of frog oocytes is associated with elaboration of an M phase inducing factor known as MPF (Masui, Y. and C.L. Markert, *J. Exp. Zool.* 177:129-146 (1971); Smith, L.D. and R.E. Ecker, *Dev. Biol.* 25:232-247 (1971)). MPF is a protein kinase in which the  
25 catalytic subunit is the frog homolog of the cdc2 protein kinase (Dunphy, W.G. et al., *Cell* 54:423-431 (1988); Gautier, J. et al., *Cell* 54:433-439 (1988); Arion, D. et al., *Cell* 55:371-378 (1988)).

Among the cyclins identified to date, the B-type cyclin has been shown to act in mitosis by serving as an integral subunit of the cdc2 protein kinase (Booher, R. and D. Beach,  
30 *EMBO J.* 6:3441-3447 (1987); Draetta, G. et al., *Cell* 56:829-838 (1989); Labbe, J.C. et al., *Cell* 57:253-263 (1989); Labbe, J.C. et al., *EMBO J.* 8:3053-3058 (1989); Meier, L. et al., *EMBO J.* 8:2275-2282 (1989); Gautier, J. et al., *Cell* 60:487-494 (1990)). The A-type cyclin also independently associates with the cdc2 kinase, forming an enzyme that appears to act earlier in the division cycle than mitosis (Draetta, G. et al., *Cell* 56:829-838 (1989); Minshull,  
35 J. et al., *EMBO J.* 9:2865-2875 (1990); Giordano, A. et al., *Cell* 58:981-990 (1989); Pines, J. and T. Hunter, *Nature* 346:760-763 (1990)). Cellular and molecular studies of cyclins in

invertebrate and vertebrate embryos have been accompanied by genetic studies, particularly in ascomycete yeasts. In the fission yeast, the *cdc13* gene encodes a B-type cyclin that acts in cooperation with *cdc2* to regulate entry into mitosis (Booher, R. and D. Beach, *EMBO J.*, 6:3441-3447 (1987); Booher, R. and D. Beach, *EMBO J.* 7:2321-2327 (1988); Hagan, I. *et al.*, *J. Cell Sci.* 91:587-595 (1988); Solomon, M., *Cell* 54:738-740 (1988); Goebel, M. and B. Byers, *Cell* 54:433-439 (1988); Booher, R.N. *et al.*, *Cell* 58:485-497 (1989)). Genetic studies in both the budding yeast and fission yeast have revealed that *cdc2* (or CDC28 in budding yeast) acts at two independent points in the cell cycle: mitosis and the so-called cell cycle "start" (Hartwell, L.H., *J. Mol. Biol.*, 104:803-817 (1971); Nurse, P. and Y. Bissett, *Nature* 292:558-560 (1981); Piggot, J.R. *et al.*, *Nature* 298:391-393 (1982); Reed, S.I. and C. Wittenberg, *Proc. Nat. Acad. Sci. USA* 87:5697-5701 (1990)). In budding yeast, the start function of the CDC28 protein also requires association of the catalytic subunit of the protein kinase with ancillary proteins that are structurally related to A and B-type cyclins. This third class of cyclin has been called the CLN class, and three genes comprising a partially redundant gene family have been described (Nash, R. *et al.*, *EMBO J.* 7:4335-4346 (1988); Hadwiger, J.A. *et al.*, *Proc. Natl. Acad. Sci. USA* 86:6255-6259 (1989); Richardson, H.E. *et al.*, *Cell* 59:1127-1133 (1989)). The CLN genes are essential for execution of start and in their absence, cells become arrested in the G1 phase of the cell cycle. The CLN1 and CLN2 transcripts oscillate in abundance through the cell cycle, but the CLN3 transcript does not. In addition, the CLN2 protein has been shown to oscillate in parallel with its mRNA (Nash, R. *et al.*, *EMBO J.* 7:4335-4346 (1988); Cross, F.R., *Mol. Cell. Biol.* 8:4675-4684 (1988); Richardson, H.E. *et al.*, *Cell* 59:1127-1133 (1988); Wittenberg, *et al.*, 1990)). Although the precise biochemical properties conferred on *cdc2*/CDC28 by association with different cyclins have not been fully elaborated, genetic studies of cyclin mutants clearly establishes that they confer "G1" and "G2" properties on the catalytic subunit (Booher, R. and D. Beach, *EMBO J.* 6:3441-3447 (1987); Nash, R. *et al.*, *EMBO J.* 7:4335-4346 (1988); Richardson, H. E. *et al.*, *Cell* 56:1127-1133 (1989)).

*cdc2* and cyclins have been found not only in embryos and yeasts, but also in somatic human cells. The function of the *cdc2*/cyclin B enzyme appears to be the same in human cells as in other cell types (Riabowol, K. *et al.*, *Cell* 57:393-401 (1989)). A human A type cyclin has also been found in association with *cdc2*. No CLN type cyclin has yet been described in mammalian cells. A better understanding of the elements involved in cell cycle regulation and of their interactions would contribute to a better understanding of cell replication and perhaps even alter or control the process.

### *Summary of the Invention*

The present invention relates to the discovery in normal eukaryotic cells, particularly human cells, that various types of cyclins (such as of the A, B, C, D, and E classes) can associate with a number of different CDKs, as well as proliferating cell nuclear antigen (PCNA), and a polypeptide (p21) of an apparent molecular weight of 21kd, so as to form multiple types of complexes. For instance, the results provided below indicate that a combination of cyclins and CDKs, along with PCNA and p21, exist in at least a quaternary complex, that many combinatorial variations of the components assemble *in vivo* (e.g., different combinations of cyclin D1 or D3 with CDK2, CDK4 and CDK5), and that each of the resulting quaternary complexes may have a subtly different role in the cell cycle or in different cell types. Thus, as described below, assays can be generated to identify agents able to, for example, selectively disrupt particular complexes formed between each member of the complex.

In addition, it has been discovered that cellular transformation is associated with selective subunit rearrangement of the cyclin D complexes. For example, the association between cyclin D, PCNA, CDKs (including CDK2, CDK4 and CDK5) and p21 is disrupted by introduction of a DNA tumor virus or its oncogenic gene product into mammalian cells. Specifically, as described herein, it has been shown that the association between cyclin D and PCNA, CDKs (CDK2, CDK4, and CDK5) and p21 is disrupted upon introduction of SV40 tumor virus or its oncogenic gene product large T antigen into human diploid cells (as exemplified by normal human diploid fibroblasts). After disassociating from cyclin D and p21, CDK4 becomes associated with a novel polypeptide of 16 kDa (p16). Similarly, cyclin A complexes also undergo subunit rearrangement. After SV40 transformation, p21 association with cyclin A is decreased or completely disassociated. Cyclin A then appears in a complex with a 19 kDa polypeptide (p19).

Likewise, it is demonstrated that non-viral transformation, such as resulting at least in part from a mutation or deletion of the p53 tumor suppressor, can result in loss of p21 from cyclin/cdk complexes. As described herein, induction of p21 in response to p53 represents a plausible mechanism for effecting cell cycle arrest in response to DNA damage, and loss of p53 may deregulate growth by loss of the p21 cell cycle inhibitor.

Thus, it is now known that p21 is associated with cyclin kinases only in normal, untransformed cells, and p16, p19 and potentially other related proteins appear to the cell cycle regulator present in transformed cells. This knowledge serves as the basis for a variety of approaches to modulating cell division by altering the activity (directly or indirectly) of cyclins. It offers specificity in modulating cell division (i.e., the ability to selectively alter

cell division in particular cell types or at a particular point in the cycle) because of the specificity of expression of cyclins in cells and the number of possible combinations of the components of the quaternary complex which appear to be formed by cyclins, CDK, PCNA and p21. In another embodiment, it offers a means by which cell division can be non-specifically altered by interfering with a common component of the quaternary complex of which D-type cyclin or A-type cyclin is a constituent, such as by interfering with PCNA. The present invention makes available an assay for detecting potential inhibitors of a particular cyclin/cdk containing quaternary complex.

In one embodiment of a therapeutic method of the present invention, formation of the quaternary complex described above is prevented or enhanced or the activity of a complex member is altered as an approach to altering cell division. Here, agents which act indirectly or directly to prevent or enhance complex formation or to alter a constituent's activity can be used. For example, as described above, catalytic activity can be inhibited by preventing activation of the protein kinase. Alternatively, PCNA inhibitors can be introduced into cells in which cell cycle start is to be inhibited, resulting in inhibition of cell division. PCNA inhibitors can act indirectly (e.g., to reduce production of PCNA by interfering with transcription or translation) or directly (e.g., to bind PCNA and prevent it from joining with other complex members). Inhibitors of p21 can also be introduced into cells and interfere, indirectly or directly, with p21 function and/or binding to the complex members. Protein-protein interactions (between or among complex components) can also be altered (reduced or enhanced) to have the desired effect on the cell cycle (to reduce or increase cell division). Agents which block such protein-protein interactions can be used. These include low molecular weight inhibitors, agents which bind to complex components (e.g., antibodies) and agents which degrade or otherwise destroy a component's ability to form a complex with the other proteins. If enhanced quaternary complex formation is desired, agents which increase the ability of complex members to interact and bind (e.g., agents which change the configuration of a complex component so that it is more available for protein-protein interactions necessary for complex formation can be introduced into cells). Enhanced complex formation can also be brought about by increasing in cells the number, activity or availability of the limiting member(s) of the quaternary complex, thus enhancing the rate at which it is formed and its availability to act.

Furthermore, it has been discovered that p21, ostensibly as an unphosphorylated or slightly phosphorylated protein, is an inhibitor of each member of the cyclin/CDK family. Phosphorylation of p21 in the quaternary complex appears to overcome this inhibition of kinase activity, allowing the cyclin/cdk/p21/PCNA complex to become activate as a cell-cycle kinase. However, the kinase activity of the activated quaternary complex is still less

than the kinase activity of cyclin/cdk binary complexes found in many transformed cell. Thus, the present invention provides a differential assay for identifying an agent that inhibits the cyclin/cdk binary complex, but does not inhibit the cyclin/cdk/p21/PCNA quaternary complex. Such inhibitors can take advantage of, for example, allosteric changes induced by the addition of p21 to cyclin/cdk complexes.

In addition, the subject invention pertains to methods of diagnosing transformation of a cell. Reagents, such as monoclonal antibodies, can be developed that recognize the interactions between the CDKs, cyclins, PCNA and the low molecular weight polypeptides (e.g., p21, p19 and p16). For example, an antibody which recognizes the interaction between p16 and CDK4 can be used to detect or diagnose transformation of many cell types. Likewise, antibodies which can distinguish between cyclin/cdk binary complexes and cyclin/cdk/PCNA/p21 quaternary complexes can be used to diagnostically test for cellular transformation. Alternatively, agents such as antibodies which recognize CDC2, CDK2, cyclin A or cyclin D, can be used to identify the subunit composition of the cyclin complexes and thus the state of transformation of the cell. Similarly, antibodies directed to p16 can be used to detect virally transformed cells, such as in a PAP smear test for Human Pappiloma virus.

The subject invention also relates to agents (e.g., oligonucleotides, antibodies, peptides) useful in the isolation, diagnostic or therapeutic methods described.

#### *Detailed Description of the Invention*

Cyclins are key regulatory proteins that, in concert with cyclin-dependent protein kinases (CDKs), function to govern critical transitions and/or restriction points during the course of cell cycle progression. The present invention provides methods and reagents for developing inhibitors and/or activators of particular cell-cycle processes. As described herein, in normal eukaryotic cells, particularly human cells, various types of cyclins (such as of the A, B, C, D, and E classes) can associate with a number of different CDKs, as well as proliferating cell nuclear antigen (PCNA), and a polypeptide (p21) of an apparent molecular weight of 21kd, so as to form multiple types of complexes. For instance, the results provided below indicate that a combination of cyclins and CDKs, along with PCNA and p21, exist in at least a quaternary complex, that many combinatorial variations of the components assemble *in vivo* (e.g., different combinations of cyclin D1 or D3 with CDK2, CDK4 and CDK5), and that each of the resulting quaternary complexes may have a subtly different role in the cell cycle or in different cell types. Thus, as described below, assays can be generated to identify agents able to, for example, selectively disrupt particular complexes formed

between cyclins and CDKs. However, as described below, while p21 is involved in complexes with various cyclins and cdk, its presence as an unphosphorylated or under phosphorylated protein in these complexes results in inhibition of the cyclin/cdk kinase activity. Phosphorylation of p21, on the other hand, appears to relieve the inhibitory effect. Similarly, overexpression of p21 can cause cell cycle arrest. Moreover, the expression of p21 in mammalian cells has been discovered to be induced by p53, such that the inhibitory effect of p21 may represent a mechanism for effecting cell-cycle arrest in response to, for example, DNA damage,

Furthermore, the present invention makes available diagnostic assays and reagents for detecting transformed cells, such as may be useful in the detection of cancer. It is demonstrated below that cellular transformation is associated with selective subunit rearrangement of the cyclin-CDK complexes. To illustrate, in cells which are transformed (either virally or by genetic aberration), the cyclin D/p21/CDK/PCNA complexes are disrupted. For instance, in virally transformed cells, CDK4 totally dissociates from cyclin D, PCNA, and p21, becoming associated instead with a 16 Kd polypeptide (termed hereinafter "p16"). Also, in p53 deficient cells, p21 is lost from the cyclin/cdk complex. Quaternary complexes containing cyclins A or B1 and p21/CDK/PCNA also undergo subunit rearrangement in transformed cells. For example, both PCNA and p21 no longer associate with CDC2-cyclin B1 binary complexes, and cyclin A complexes no longer contain p21, which is replaced instead with a 19kd protein (p19). Detecting such abnormal subunit complexes can thus be used predictively to detect of cellular transformation. For example, the present invention makes available reagents, including antibodies and nucleic acid probes, for detecting altered complex formation and/or increased levels of p16 expression in order to identify transformed cells.

In addition, p16 is demonstrated below to exert an inhibitory effect on the activity of cyclin/CDK complexes, particularly those which include CDK4. For instance, p16 is able to inhibit the activity of cyclin D1/CDK complexes *in vivo*. As is generally known, cyclin D1 has been associated with a wide variety of proliferative diseases. Thus, the present invention identifies a potential inhibitor of cell proliferation resulting from oncogenic expression of cyclin D1.

Conversely, p16 can be used in assays to identify agents which decrease the ability of p16 to bind CDK4 and thereby relieve inhibition of cyclin/CDK4 complexes. In this embodiment, the reactivation of the CDK4/cyclin complexes disrupts or otherwise unbalances the cellular events occurring in a transformed cell. Such agents can be of use therapeutically to activate CDK4 complexes in cells transformed, for example, by tumor viruses. Treatment of such cells can result in enhancement of otherwise virally-suppressed

cell-cycle checkpoints, such as p53, and results in the accumulation of the infected cell at the checkpoint, or alternatively, in the instance of Rb phosphorylation, cause premature progression through a checkpoint so as to result in cell death.

*Intro 5 1 2* A cyclin-dependent kinase, designated CDK5, and DNA encoding CDK5 are also available as a result of the work described herein. CDK5 has been shown to co-precipitate with D-type cyclins, PCNA and p21. Thus, the present invention contemplates that CDK5 function and/or association with other members of the complex can be altered (enhanced or decreased) to effect the proliferation of a cell. If CDK5 is prevented from binding to D-type cyclin, kinase activation will be prevented. This can be effected as described below.

10

#### I. Cyclin complexes in normal cells

The following is a description of the discovery that cyclins are associated with at least  
15 three additional polypeptides (a CDK, PCNA and p21) in what appears to be a quaternary complex having many possible combinatorial variations resulting in complexes that may each have distinct roles in the cell cycle, or in different cell types.

As described below and in Example 1, immunological procedures have been used to establish that cyclins associate, in eukaryotic cells, with a variety of potential catalytic  
20 subunits (e.g., CDKs, such as CDK2, CDK4 and CDK5). In addition, these procedures have shown that, in untransformed cells, cyclin/CDK complexes can further associate with the replication factor PCNA and a polypeptide of 21 kDa apparent molecular weight.

To illustrate, human cyclin D1 has been associated with a wide variety of proliferative diseases. As described herein, in human diploid cells, specifically human diploid fibroblasts,  
25 cyclin D1 is complexed with a number of other cellular proteins. Among them are the catalytic subunits CDK2, CDK4 (previously called PSK-J3), and CDK5 (also called PSSALRE). In addition, polypeptides of 21 kDa and 36 kDa are identified in association with cyclin D1. As described in Example 1, it has been shown that the 36 kDa protein is the Proliferating Cell Nuclear Antigen, PCNA. PCNA has been described as an essential  
30 accessory factor to the delta polymerase, which is required for leading-strand DNA replication and DNA repair. Cyclin D3 also associates with multiple protein kinases, p21 and PCNA, as shown herein. It is proposed that there exists a quaternary complex of D type cyclins, CDK, PCNA and p21, and that many combinatorial variations (cyclin D1, D3 with CDK2, 4 and 5) may assemble *in vivo*. These findings link a human putative G1 cyclin that  
35 is associated with oncogenesis with a well characterized DNA replication and repair factor. Likewise, the presence of PCNA and P21 in quaternary complexes with cyclins and cdks is demonstrated below for a number of cyclin/cdk pairs.



(i) *Investigation of Proteins that Associate with Cyclin D*

To identify proteins that specifically associate with cyclin D, anti-cyclin D1 immunoprecipitates of [<sup>35</sup>S] methionine-labelled WI38 human diploid fibroblasts lysates were examined (see Example 1, Experimental Procedures). WI38 cells were initially chosen for this study because they are a relatively normal cell line that expresses reasonably high levels of cyclin D1 and a low level of cyclin D3 mRNA (Won *et al.*, *Proc. Natl. Acad. Sci.* (1992). Human 293 transformed primary embryonal kidney cells were used as controls because they express all three D cyclin mRNAs and proteins at extremely low levels (Xiong, *et al.*, *Cell* 65:691-699 (1991)). WI38 cells express a readily detectable 35 kDa polypeptide that can be immunoprecipitated by the anti-cyclin D1 antiserum. The identity of the 35 kDa protein as cyclin D1 was confirmed by comparison of an immunoprecipitate of the same WI38 cell lysate with pre-immune serum, and with a similar precipitation of 293 cell lysate with the same anti-cyclin D1 antiserum. Because of the existence of three closely related cyclin D genes in human cells, and weak cross-reactivity of the anti-cyclin D1 antibody to other cyclin D proteins, the identity of the 35 kDa band was further investigated by partial proteolytic mapping. *S. aureus* V8 partial proteolysis of the 35 kDa band revealed the same pattern as that of similar cleaved cyclin D1 synthesized *in vitro*, but not as that of cyclin D2 or D3.

In addition to the intense 35 kDa band corresponding to cyclin D1, three other major bands, p36, p33 and p21 and one minor band, p31 (where the number indicates the apparent molecular weights), appeared specifically in the anti-cyclin D1 precipitates. These polypeptides are absent from precipitates of WI38 cell lysate using pre-immune serum or precipitates of 293 cell lysates with the same anti-cyclin D1 antibody. The possibility that any of these four bands, in particular p31 and p33, might be cyclin D2 or D3 was ruled out by comparing their partial V8 proteolysis patterns with those of *in vitro* translated D2 and D3. Precipitation of these polypeptides with anti-cyclin D1 serum is also not likely to be due to the presence of cross-reactive epitopes in any of these proteins, as these proteins were not detected when immunoprecipitation was coupled with Western blotting using the same anti-cyclin D1 antibody. Experiments to identify the cyclin D1-associated proteins are described below.

(ii) *CKD5 Associates with D-Type Cyclins*

It has been previously reported that in murine macrophages, cyclin D1/*cyll* associates with a polypeptide that cross-reacts with an antibody to full-length p34cdc2 of *Schizosaccharomyces pombe* (G8), but not with an antibody prepared against the C-terminus

of human p34cdc2 (Draetta *et al.*, *Cell* 50:319-325 (1987); Draetta and Beach, *Cell* 54:17-26. (1988); Matsushime *et al.*, *Cell* 65:701-713 (1991). Essentially identical results were presently obtained in human W138 cells, suggesting that cyclin D1 associates with a relative of human CDC2.

5       The G8 antibody was used to screen human cDNA expression libraries (see Example 1, Experimental Procedures), in order to isolate putative D-type cyclin-associated kinases. Thirty four G8-positive cDNA clones were identified from a HeLa cell cDNA library. Among these, 17 clones encoded CDC2 and another 14 encoded for CDK2. One of the  
10       remaining clones encodes an ORF of 292 amino acid residues (SEQ ID Nos. 1 and 2) with a predicted molecular weight of 33,283 daltons. This clone is designated CDK5, since it shares extensive amino acid identity to the known cyclin-dependent kinases (CDKs), including *S. pombe* CDC2 (53.4%), *S. cerevisiae* CDC28 (55.9%), human CDC2 (56.8%), and human CDK2 (60.3%), and associates with human D-type cyclins (see below). CDK5 encodes a sequence of DLKKYFD at amino acid sequence 86 to 92, while the corresponding region of  
15       human CDC2 has the sequence of DLKKYLD and CDK2 has DLKKFMD.

      To determine whether CDK5 associates with D cyclins, an antiserum was raised against a peptide corresponding to the unique carboxy-terminal region of CDK5 (see Example 1, Experimental Procedures). This serum does not cross react with human CDC2, CDK2, or CDK4. Immunoprecipitation or Western-blotting following immunoprecipitation  
20       showed that this antiserum detected a polypeptide in cell lysate with an apparent molecular weight of 31 kDa (p31), which co-migrated with CDK5 polypeptide synthesized *in vitro*, and whose signal was effectively competed away by the CDK5 antigenic peptide. The identity of the 31 kDa protein precipitated by the anti-CDK5 antibody was further confirmed to be CDK5 by comparing the partial V8 proteolytic mapping of p31 with *in vitro* translated  
25       CDK5.

      Immunoprecipitation of cell lysates of <sup>35</sup>S-methionine labeled W138 cells using the anti-CDK5 antiserum revealed several polypeptides, in addition to p31<sup>CDK5</sup>. Among these, polypeptides of 36 kDa (p36), p35 kDa (p35), 33 kDa (p33) and 21 kDa (p21) were most prominent and specifically coprecipitated by the anti-CDK5 antiserum. All four polypeptides  
30       were absent from precipitates with the pre-immune serum or in the presence of excess amount of the CDK5 carboxy-terminal peptide.

      The electrophoretic mobilities of p35 and p33 were found to be the same as that of *in vitro* translated human cyclin D1 and D3, respectively. To directly test the possibility that the CDK5-associated p35 might correspond to cyclin D1, CDK5 immunoprecipitates were  
35       blotted with anti-cyclin D1 antisera. A 35 kDa polypeptide, which co-migrated with p35<sup>cyclin D1</sup>, was detected by the anti-cyclin D1 antiserum. Reciprocal blotting of anti-cyclin

Sub. I 3  
D1 immunocomplexes by the CDK5 antiserum also revealed the presence of a 31 kDa polypeptide which had the same mobility as p31<sup>CDK5</sup>. Similarly, CDK5 has also been detected in anti-cyclin D3 immunoprecipitates. These data indicate that the CDK5-associated p35 is cyclin D1, and CDK5-associated p33 is cyclin D3.

5 To seek conclusive evidence of the identity of the CDK5-associated p35 and p33 proteins, partial proteolytic mapping was employed (Cleveland *et al.*, *J. Biol. Chem.* 252:1102-1106 (1977)). <sup>35</sup>S-labelled p35 purified from anti-CDK5 immunoprecipitates was subjected to partial *S. aureus* V8 protease digestion and compared with similarly treated human p35<sup>cyclinD1</sup> obtained either from *in vitro* translation or from an anti-cyclin D1  
10 immunoprecipitation. The V8 proteolytic pattern of p35 from anti-CDK5 immunoprecipitates was identical to that of cyclin D1, but distinct from that of cyclin D3. Similar experiments were also performed to confirm the identity of p33. The partial proteolytic pattern of the CDK5-associated p33 is identical to that of an *in vitro* translated human cyclin D3, but not D1. Conversely, it has also been determined that the partial V8 digestion pattern  
15 of the cyclin D1-associated p31 is identical to CDK5 obtained either from *in vitro* translation or anti-CDK5 immunoprecipitation.

(iii) *CDK2 Associates with Cyclin D*

The apparent molecular weight of the cyclin D1-associated p33 (e.g. in the anti-cyclin  
20 D1 precipitates; section (i) above), and also the cross reactivity of p33<sup>CDK2</sup> with the G8 antibody suggests the possibility that p33 might be CDK2. To test this, anti-CDK2 precipitate of a [<sup>35</sup>S] methionine-labelled WI38 cell lysate was compared with an anti-cyclin D1 precipitate. As expected, the anti-C terminal CDK2 serum precipitated a 33 kDa protein which was confirmed to be p33<sup>CDK2</sup> by comparing the partial *S. aureus* V8 proteolysis  
25 pattern of the 33 kDa band with that of *in vitro* translated CDK2. Moreover, p33<sup>CDK2</sup> comigrated with the p33 present in the anti-cyclin D1 precipitate. Reciprocally, anti-CDK2 antiserum also precipitated a 35 kDa protein which comigrated with cyclin D1.

To seek further evidence for the existence of a possible association between CDK2 and cyclin D1, a WI38 cell lysate was immunoprecipitated with anti-cyclin D1, separated on  
30 SDS-PAGE, and immunoblotted with anti-CDK2 antiserum. The anti-CDK2 antibody was raised against a carboxy-terminal peptide (Pagano *et al.*, *EMBO J.* 11:961-971 (1992)) and its specificity was checked by immunoblotting bacterially-expressed human CDC2, CDK2, CDK3, CDK4 and CDK5. Only CDK2, and not the other four CDK proteins, was recognized by this antibody. CDK2 protein was detected in WI38 cell lysates that were  
35 immunoprecipitated with either anti-CDK2 or anti-cyclin D1, but not in lysate precipitated with pre-immune serum or with anti-CDK2 pre-incubated with competing antigenic peptides.

In a reciprocal Western blot experiment, cell lysate was immunoprecipitated with anti-CDK2 and blotted with anti-cyclin D1. Cyclin D1 was detected in the anti-cyclin D1 and anti-CDK2 immunoprecipitates, but not in precipitates from either preimmune serum or anti-CDK2 antiserum pre-incubated with a competing CDK2 peptide.

5        To test whether CDK2 also associates with cyclin D3, immunoprecipitates formed using antiserum to the C-terminal peptide of human cyclin D3 (see Example 1, Experimental Procedures) were blotted with anti-CDK2 antiserum. CDK2 was weakly detected in the anti-cyclin D3 precipitate, but not in the control precipitate with anti-cyclin D3 antiserum pre-incubated with a competing antigen peptide.

10        Finally, to further confirm the association between CDK2 and cyclin D, partial proteolytic mapping experiments were conducted. Initially, attempts were made to proteolytically map the cyclin D1-associated p33 to compare it with CDK2. However, because of the comigration of CDK2 with yet another predominant protein kinase in the anti-cyclin D1 precipitates (see section (iv) below), a different proteolytic pattern was obtained.  
15        Therefore, the converse experiment was performed. The 35 kDa band in anti-CDK2 immunoprecipitates was excised from SDS-polyacrylamide gel, partially digested with V8 protease and electrophoretically separated and compared with V8 digested p35<sup>cyclin D1</sup> derived either from *in vitro* translation or from an anti-cyclin D1 immunoprecipitation. The pattern of proteolytic cleavage was the same in each case.

20        (iv) *pSK-J3/CDK4 is the Predominant p33 Protein Associated with Cyclin D1*

      The difference in the proteolytic pattern of cyclin D1-associated p33 from that of CDK2 suggested that the majority of D1-associated p33 corresponds to a protein other than CDK2. A protein kinase called PSK-J3, originally identified in a screen with mixed  
25        oligonucleotide probes derived from conserved regions of serine/threonine kinases (Hanks, S.K., *Proc. Natl. Acad. Sci. USA* 84:388-392 (1987)), was believed to have cyclin D binding properties. The predicted molecular mass of PSK-J3 is 34 kDa, close to that of p33. Because of its association with D cyclins, as demonstrated below, PSK-J3 is referred to hereinafter as CDK4. *In vitro* translated CDK4, and that precipitated from a cell lysate with anti-CDK4  
30        serum, demonstrated the same electrophoretic mobility as CDK2 and the D1-associated p33. The identify of CDK4 precipitated by the anti-CDK4 antiserum was confirmed by comparing its partial V8 mapping pattern to that of *in vitro* translated CDK4.

      Immunoprecipitation-Western blotting experiments were carried out to directly test whether the cyclin D1-associated p33 is CDK4. An anti-CDK4 serum reacted with a 33 kDa  
35        protein present in anti-cyclin D1 immunoprecipitates that has the same mobility as the CDK4 precipitated by anti-CDK4, but did not react with cell lysate precipitates of either CDK2 or

CDK5. Reciprocally, the anti-CDK4 antiserum also precipitated a 35 kDa protein detected by anti-cyclin D1 antibody. To further confirm the identity of the cyclin D1-associated p33, the partial V8 digestion pattern of p33 was compared to that of immunoprecipitated CDK4 and CDK2. The cyclin D1-associated p33 displayed a very similar pattern to that of CDK4, but was quite dissimilar to that of CDK2. This result indicates that CDK4 is considerably more abundant (at least as crudely assayed by methionine labelling) than CDK2 in anti-cyclin D1 precipitates of WI38 cells. Similarly, a 33kDa polypeptide (p33) seen in anti-CDK4 immunoprecipitate has been identified to be cyclin D3 by partial V8 peptide mapping.

10 (v) *Association of p21 with Cyclin D1 and CDK2*

In [<sup>35</sup>S] methionine-labelled WI38 lysate precipitated with anti-cyclin D1 serum, a 21 kDa protein (p21) appeared to associate specifically with cyclin D1. p21 was not present in the precipitates with pre-immune serum, nor in the anti-cyclin D1 precipitate derived from 293 cells, which contain undetectable levels of cyclin D1. Specific association of p21 with cyclin D1 was further supported by the presence of a comigrating 21 kDa protein in immunoprecipitates formed with sera against CDK2, CDK4 and CDK5. When anti-CDK2 antiserum was pre-blocked with a competing CDK2 peptide, the p21 band, and also p33<sup>CDK2</sup> and p35<sup>cyclin D1</sup> were not seen. Similarly, p21 was also absent from anti-CDK5 immunoprecipitates if the antiserum was pre-incubated with the CDK5 carboxy-terminal antigen peptide. p21 was not recognized in Western blots by any of the anti-CDK or anti-cyclin D antibodies used in this study. Furthermore, although the total immunoprecipitable CDK2 in 293 cells is similar to that in WI38 cells, the p21 band was not present in the CDK2 immunoprecipitates from 293 cell lysates.

To determine whether the p21 from cyclin D1 immunoprecipitates and CDK2 immunoprecipitates correspond to the same polypeptide, the partial V8 proteolytic pattern of the p21 purified from each source were compared. They are indeed the same. The p21 precipitated by anti-CDK5 antiserum was also found to be the same as cyclin D1-associated p21. The p21 in the anti-CDK4 immunoprecipitation was also proteolytically mapped. It gave an identical pattern to the cyclin D1-associated p21. p21 does not correspond to the human max protein or p21<sup>ras</sup>, as its electrophoretic mobility is faster than that of either and it was not recognized by an anti-human ras antibody on Western blots.

(vi) *Cyclin D1-Associated p36 is PCNA*

As set out above, anti-cyclin D1 precipitates of WI38 cells show associated polypeptides of 21 kDa, 31 kDa and 33 kDa and also a prominent protein of 36 kDa. p36 was not detected in control precipitates, using either pre-immune serum or in 293 lysates. A

36 kDa protein, in a lower abundance was also detected in CDK2, CDK4 and CDK5 immunoprecipitates, but not in the precipitates with antiserum pre-incubated with competing peptides.

While attempting to establish the identity of the p36, four observations suggested the possibility that it might be the human proliferating nuclear antigen, PCNA. First, in an asynchronous population of proliferating WI38 cells, cyclin D1 was observed to be predominantly a nuclear protein, although the distribution is not identical to the speckled pattern of PCNA (Bravo, R. and H. MacDonald-Bravo, *EMBO J.*, 4:655-661 (1985); Madsen, P. and J.E. Celis, *FEBS Lett.*, 193:5-11 (1985). Second, while the level of cyclin D1 is relatively constant in mitogenically activated WI38 cells, the p36 in [<sup>35</sup>S] methionine-labelled cyclin D1 immunoprecipitates was low in quiescent cells and increased at 10-14 hours after stimulation. Ten to fourteen hours after serum stimulation, many WI38 cells are in the late G1, a time which coincides with the onset of PCNA synthesis in serum-stimulated 3T3 fibroblasts (Bravo, R. and H. MacDonald-Bravo, *EMBO J.*, 3:3177-3181 (1984); Celis, J.E. and A. Celis, *Proc. Natl. Acad. Sci., USA*, 82:3262-3268 (1985); Madsen P. and J.E. Celis, *FEBS Lett.*, 193:5-11 (1985). Third, the apparent molecular weight of p36 is similar to that of PCNA. Finally, anti-PCNA antibody precipitated a 35 kDa polypeptide whose electrophoretic mobility is similar to that of p35<sup>cyclin D1</sup>. The identity of the p36 precipitated by the anti-PCNA antibody has been confirmed as PCNA by comparing its V8 peptide map to that of *in vitro* translated PCNA.

Immunoprecipitation-Western blot experiments were carried out to test directly the possibility that p36 is PCNA. PCNA was readily detected in anti-cyclin D1, cyclin D3, CDK2 and CDK5 immunoprecipitates, but not in the respective control precipitates. In a reciprocal experiment, cyclin D1 and CDK2 were also detected in anti-PCNA immunoprecipitates. It has not been possible to convincingly detect cyclin D3 or CDK5 in PCNA precipitates, possibly due to the low abundance of both proteins in WI38 cells and the relatively poor sensitivity of the D3 and CDK5 antisera in Western blots.

To further assess the similarity between the PCNA and the p36 polypeptide associated with cyclin D1 and CDK2, p36 bands were purified from cyclin D1 and CDK2 immunoprecipitates, separated on SDS-PAGE and their partial V8 proteolytic mapping pattern was compared with that of PCNA. Digestion of cyclin D1-associated p36 by V8 protease revealed the same pattern as that of PCNA derived from anti-PCNA immunoprecipitates and *in vitro* translated PCNA. Similarly, the digestion patterns of CDK2- and CDK5-associated p36 also match to that of PCNA. The p36 associated with cyclin D1 is PCNA. In addition, proteolytic mapping of the p21 detected in anti-PCNA

immunoprecipitate demonstrated it to be the same as cyclin D1-associated p21 described above.

(viii) *Subunit complexes of other cyclins*

5           PCNA and p21 not only associate with cyclin D-CDK to form a quaternary complex as described above, but also are present as universal components of cyclin-CDK complexes in many other normal cells example. In lysates of WI38 cells and HSF43 cells immunoprecipitated with anti-cyclin A antibody, it was found that cyclin A associates with PCNA, CDC2, CDK2, and p21.

10           Likewise, analysis of <sup>35</sup>S-methionine-labeled anti-cyclin B1 immunoprecipitates from WI38 and HSF43 lysates revealed a quaternary complex, comprising cyclin B1, a CDK, p21 and PCNA.

          Although the experimental techniques used in this study do not formally allow a distinction between the existence of multiple pair-wise interactions between each protein, the data are most simply explained if D cyclin, PCNA, CDK and p21 form a quaternary complex. Comparison of the intensity of the methionine-labelled bands in the immunoprecipitation reactions suggest that not all the cyclin D is present in the complex, nor is all the PCNA. However, the relative intensity of the p36 (PCNA), p33 (CDK4) and p21 bands in an anti-cyclin D precipitate is very similar. The results presented herein do not rule out the possibility that cyclin D, with or without the associated proteins described here, might associate with additional partners *in vivo*. In particular, two polypeptides that migrate either side of the 97KD molecular weight marker are apparent in anti-cyclin D precipitation reaction.

          PCNA has been described as an essential accessory factor to the delta polymerase, that is required both for leading-strand DNA replication and also for DNA repair (Prelich, G. *et al.*, *Nature*, 326:517-520 (1987); Prelich G. and B. Stillman, *Cell*, 53:117-126 (1988); Toschi, L. and R. Bravo, *J. Cell Biol.* 107:1623-1628 (1988); M.K.K. Shiviji, *et al.*, *Cell*, 69:367-374 (1992). It localizes in the nucleus at sites of active DNA synthesis and the localization of PCNA, but not its synthesis, is dependent on DNA synthesis. It was not possible to detect phosphorylation of any of the respective subunits in *in vitro* kinase reactions, suggesting that neither PCNA nor p21 is a primary substrate of cyclin D/CDK.

          The cyclin/CDK enzymes that associate with PCNA and p21 might assemble *in vivo* into a more elaborate multi-protein-DNA synthetic complex, one component of which might be the physiological substrate of the particular cyclin D/CDK complex. PCNA has generally been biochemically purified from cells in a monomeric form that is unassociated with other proteins (Prelich, G. *et al.*, *Nature* 346:760-763 (1987)). It is possible that the multi-protein

complexes described in the present study were over-looked because they do not comprise the majority of the cellular PCNA. Alternatively, it is possible that PCNA has further non-DNA synthetic cell cycle regulatory roles that have not previously been described and that involve cyclin D and CDK proteins. However, the present studies do provide the first biochemical  
5 indication of a possible function of cyclins, as modulators of PCNA function.

## II. Cyclin Complexes in Transformed Cells

The importance of the quaternary complex is emphasized by the discovery that  
10 cellular transformation by DNA tumor viruses is associated with selective subunit rearrangement of the cyclin D complexes, as well as other cell-cycle complexes, including cyclin A, CDC2, CDK2, CDK4 and CDK5 complexes. In particular, introduction of SV40 DNA tumor virus or its oncogenic gene product large T antigen into normal human diploid fibroblasts (HDF) causes disruption of the association between cyclin D and PCNA, CDKs  
15 (such as CDK2, CDK4 and CDK5) and p21. After dissociation from cyclin D and p21, CDK4 kinase becomes associated with a 16 kDa polypeptide (p16). Similarly, SV40 transformation causes a decrease of association of p21 with cyclin A in HDF; and adenovirus-(293 cell line) or human papilloma virus- (HeLa cell line) transformed cells, p21 is completely disassociated from cyclin A. A 19-kDa peptide, p19, then appears in a complex  
20 with cyclin A. Therefore, p21 is associated with cyclin kinases only in normal, untransformed cells, whereas p16, p19 and possibly other related proteins are present in cyclin complexes in transformed cells.

As described below, the present observations provide striking evidence that the cyclin/CDK family of enzymes that act at multiple key steps in the cell division are grossly  
25 altered in a variety of oncogenically transformed cells. In each member of the cyclin/CDK family examined, association with PCNA and p21 was observed in normal cells. However, upon transformation with the DNA tumor virus SV40, or its transforming antigen (T), the cyclin/CDK/PCNA/p21 complexes are disrupted. For example, in transformed cells, CDK4 totally dissociates from cyclin D, PCNA, and p21 and, instead, associate exclusively with a  
30 polypeptide of 16kd (p16). Quaternary complexes containing cyclins A or B1 and p21/CDK/PCNA also undergo subunit rearrangement in transformed cells. Both PCNA and p21 are no longer associated with CDC2-cyclin B1 binary complexes. Cyclin A complexes no longer contain p21, rather, a new 19 kd polypeptide (p19) is found in association with cyclin A. This pattern of subunit rearrangement of cyclin-CDK complexes has been  
35 discovered not only in SV40-transformed cells, but also in cells transformed with adenovirus or papilloma virus. Moreover, the pattern of subunit composition of the cyclin-CDK family



was grossly abnormal in non-virally transformed cells, such as the p53-deficient cells derived from Li-Fraumeni patients, as well as the epidermal A-431 carcinoma cell, and the pharynx squamous cell carcinoma FaDu. In these transformed cells, p21 was missing from each of the cyclin/cdk complexes

5

*(i) Disruption of cyclin D/CDK/PCNA/p21 complexes in SV40-transformed cells*

While cyclin D/CDK/PCNA/p21 quaternary complexes were detected in normal fibroblast cells (e.g. WI38 and HS68) as described above, such complexes were not detected in several other cell lines that had been virally transformed (e.g. the human 293 cell line).  
10 Given the apparent difference, the subunit compositions of cyclin D complexes in normal diploid fibroblasts and their transformed derivatives were more closely compared. The WI38 VA13, subline 2RA (hereafter referred to as VA13), is an SV40 virus-transformed derivative of the WI38 cell line. Anti-cyclin D1 immunoprecipitates of <sup>35</sup>S methionine-labeled WI38 and VA13 lysates were examined. As demonstrated above for WI38 cells, the anti-cyclin D1  
15 antiserum precipitates a dominant 35-kD band corresponding to cyclin D1 and three major associated proteins, p36<sup>PCNA</sup>, p33<sup>CDK4</sup>, and p21. In SV40-transformed VA13 cells, the level of cyclin D1 is decreased by two- to threefold as determined by autoradiography of <sup>35</sup>S methionine-labeled immunoprecipitates, and by Western blotting. However, none of the three major cyclin D1-associated proteins was visibly associated with cyclin D1 in SV40  
20 transformed VA13 cells. Reciprocal immunoprecipitations were carried out with anti-CDK4 and anti-CDK2 antisera to confirm the observed disruption of cyclin D complexes in SV40 - transformed cells. In WI38 cells, anti-CDK4 antibody precipitated CDK4 in addition to three major associated proteins, p36<sup>PCNA</sup>, p35<sup>cyclin D1</sup>, and p21. In SV40-transformed VA13 cells, whereas CDK4 is present at a similar level compared with untransformed WI38 cells,  
25 no detectable PCNA, cyclin D1, or p21 was present in the anti-CDK4 immunoprecipitates. Similar results were also observed in immunoprecipitates with anti-CDK2, another cyclin D-associated kinase catalytic subunit. Cyclin D1 is one of the major CDK2-associated proteins in WI38 cells, but the association is undetectable in SV40-transformed VA13 cells, even though the level of CDK2 is similar or slightly higher in the transformed cells. Also,  
30 the level of CDK2-associated p21 was reduced in transformed cells, but is present at a detectable level.

Several additional normal human diploid fibroblast cell lines and their SV40-transformed derivatives were examined. HSF43, a diploid fibroblast cell line derived from neonatal foreskin and CT10-2C-T1 (hereafter referred to as CT10), was obtained from  
35 HSP43 by introduction of a plasmid containing the SV40 large tumor antigen gene driven by a Rous sarcoma virus (RSV) promoter (Ray et al. *J Cell Biochem* 42:13-31, (1990)). The

pattern of subunit composition and dissociation of the normal and transformed cells was very similar to that observed in the WI38 and VA13 cells. No cyclin D1 was seen in anti-CDK4, anti-CDK2, and anti-CDC2 immunoprecipitates prepared from T-transformed CT10 cells, but it was apparent in the HSF43 cells. Reciprocally, CDK4 was not seen in anti-cyclin D1 precipitates in CT10 cells. CDK4-associated PCNA and p21 were also not detected in CT10 cells. p21 in the T-transformed cells appeared to be replaced by a newly identified pl6 protein as in the VA13 cell line. In addition, essentially identical results were also obtained from other pairs of human fibroblast cell lines, IMR-90, a normal human lung diploid fibroblast cell line and its T-transformed derivative IDH4 (Shay et al. *Biochem Biophys Acta* 1072:1-7 (1992)), as well as a pair of monkey cell lines, CV-1, a pseudodiploid kidney cell line, and its SV40-transformed derivative COS-1.

To further confirm the observed dissociation of cyclin D complexes in transformed cells, immunoprecipitation coupled with immunoblotting experiments, was performed to avoid potential artifacts that can sometimes arise in metabolic labeling experiments. Total lysates prepared from either untransformed WI38 or SV40-transformed VA13 cells were immunoprecipitated with a battery of antibodies, separated electrophoretically, and blotted with various secondary antibodies. CDK4, CDK2, and PCNA were either not detected (CDK4) or were present at dramatically decreased levels (CDK2 and PCNA) in anti-cyclin D1 precipitates derived from SV40-transformed cells. In each case, direct immunoblotting confirmed that the absolute level of CDK4, CDK2, and PCNA is similar in normal and transformed cells. Reciprocally, cyclin D1 was not detected in either anti-CDK2 or anti-CDK4 precipitates derived from transformed VA13 cells. The same results were also obtained from each of the other pair of cell lines, HSF43 and CT10.

(ii) *Subunit rearrangement of cyclin A and B complexes in transformed cells*

The subunit composition of cyclin A complexes in untransformed WI38 cells and SV40-transformed VA13 cells were examined. As described above, cyclin A associates with p36<sup>PCNA</sup>, p33<sup>CDC2</sup>, p33<sup>CDK2</sup>, and p21 in WI38 cells. In SV40-transformed VA13 cells, the level of both cyclin A itself and cyclin A-associated CDC2/CDK2 increased approximately threefold. Reciprocally, the level of CDC2- and CDK2-associated cyclin A is also increased two- to threefold..

The level of cyclin A-associated p21, as determined by immunoprecipitation of <sup>35</sup>S methionine-labeled cell lysates, is reduced in VA13 cells as compared with WI38 cells. A low level of p21 is also present in the immunoprecipitates prepared from VA13 cells using antisera against CDK2, the major catalytic partner of cyclin A. Consistently, the same results

were obtained using HSF43 and CT10 cells, in addition to normal IMR-90 cells versus their T-transformed IDH cells, and monkey CV-1/COS-1 pair cell lines.

5 A number of other polypeptides were noticed in cyclin A precipitates that are specific to untransformed cells or to transformed cells. For example, a protein with a molecular mass of 42 kD is seen as a predominant band in untransformed WI38 or HSF43 cells but not in transformed VA13 or CT10 cells. Conversely, a polypeptide of 95 kD, which might correspond to the T antigen, is seen only in transformed cells, as is a 19 kd polypeptide (discussed below).

10 The subunit composition of cyclin B1 complexes in normal and transformed cells was also examined. In common with cyclin D1, the quaternary complex of cyclin B1/CDK/p21/PCNA is altered in both SV40-transformed VA13 cells and T-transformed CT10 cells as compared with nontransformed WI38 and HSF43 cells. Thus, neither PCNA nor p21 associates with cyclin B/CDK in the transformed cells. However, as anticipated, CDC2 is associated with cyclin B1 (p62) in VA13, CT10, 293, and HeLa cells.

15

*(iii) Cyclin and CDK complexes in other DNA tumor virus-transformed cells*

To investigate whether cyclin-CDK complexes are also altered in other human tumor cells, papilloma virus-containing cervix carcinoma HeLa cells and adenovirus-transformed primary kidney 293 cells were examined for the subunit composition of various cyclin and CDK complexes. Both of these cell lines have been used widely in biochemical studies of the mammalian cell cycle. Cyclin D1 is expressed at a low level in HeLa cells and is barely detectable in 293 cells. The subunit composition of other cyclin/CDK complexes, however, can be investigated. The well-established association of CDC2-cyclin B1, CDC2-cyclin A, and CDK2-cyclin A were all readily detected in both HeLa and 293 cells. However, no p21 was observed in anti-CDC2, anti-CDK2, anti-cyclin A, or anti-cyclin B1 immunoprecipitates from either HeLa or 293 cells. Thus, the quaternary complexes of cyclin A/CDK/p21/PCNA and cyclin B1/CDK/p21/PCNA are either not assembled or are present at extremely low levels in these DNA tumor virus-transformed cells. In fact, a new cyclin A complex appeared, in which p21 seems to be replaced by a polypeptide of 19 kD. A similar 19 kD polypeptide is present in anti-cyclin A precipitates from SV40-transformed human VA13, CT10, IDH4, and even monkey COS-1 cells. Furthermore, in 293 and HeLa cells, the subunit composition of CDK4 is identical to that of the T-antigen-transformed cells. Cyclin D1 is not associated with CDK4 (trivially attributable to absence of cyclin D from the cell), but PCNA and p21 are also absent. p21 has been replaced by p16 in HeLa and 293 cells. Interestingly, CDK4-associated p16 is detected at very low levels in untransformed WI38 or HSF43 cells. Proteolytic cleavage mapping in each case revealed that the CDK4-associated p16 from HeLa, 293, VA13

and WI38 cells is identical, but different from p21. The presence of p19 and p16 in cells transformed by three different viruses and p16 in untransformed cells indicates that they are not virally encoded proteins.

5 (iv) *Alteration of cyclin and CDK complexes in Li-Fraumeni cells*

Fibroblasts from familial Li-Fraumeni patients exhibit an elevated rate of spontaneous abnormalities, including aneuploidy and immortalization (Li et al. *J Natl Cancer Inst* 43:1365-1373 (1969); and Bischoff et al. *Cancer Res* 50:7979-7984 (1990)). These cells do not contain any known viruses; instead single-base heterozygous mutations of the tumor  
10 suppressor gene p53 are the only reported germ-line alteration. Escape from senescence and spontaneous immortalization of Li-Fraumeni fibroblasts during continued passage *in vitro* is associated with secondary loss of the wild-type p53 allele. <sup>35</sup>S methionine-labeled cell lysates from a spontaneously immortalized Li-Fraumeni cell line, LCS041 (passage >170) were immunoprecipitated with a variety of antibodies and analyzed by SDS-PAGE. The level  
15 of most of these proteins in LCS041 cells is similar to that in normal diploid fibroblasts as determined by metabolic labeling and immunoblotting, except that cyclin A is expressed at a much lower level compared with normal fibroblasts. The subunit composition of cyclin and CDK complexes is grossly abnormal in LCS041 cells. cyclin B1-CDC2 complexes exist, as in HeLa and 293 cells, and are not associated with p21 or PCNA. The cyclin D1-CDK4 as-  
20 sociation is reduced to a barely detectable level in LCS041 cells, and both PCNA and p21 are absent. p21 was not detected in any of the cyclin-CDK complexes investigated in LCS041 cells and did not appear to be replaced by p16 or p19 proteins as occurs in T-anti-gen-transformed fibroblasts. The level of PCNA associated with cyclin-CDK complexes is also dramatically reduced in every case. Direct immunoblotting demonstrated that the  
25 abundance of PCNA is higher in LCS041 cells, compared with normal fibroblasts, but PCNA is dramatically reduced or entirely absent from immunocomplexes isolated with anti-CDC2, CDK2, CDK4, cyclin A, cyclin B1, and cyclin D1. Essentially identical results were also obtained by use of another Li-Fraumeni cell line, LCS087. This suggests that loss of p53 alone might be sufficient to alter the subunit composition of the cell-cycle kinases.

30

### III Role of p21 in cell-cycle regulation

Deregulation of cell proliferation is a hallmark of neoplastic transformation.  
35 Alteration in growth control pathways must translate into changes in the cell cycle regulatory machinery, but the mechanism by which this occurs is largely unknown. As described above,

compared to normal human fibroblasts, cells transformed with a variety of viral oncoproteins show striking changes in the subunit composition of the cyclin dependent kinases . In normal cells, CDKs exist predominantly in multiple quaternary complexes, each containing a CDK, cyclin PCNA and p21. However, in many transformed cells PCNA and p21 are lost from these multiprotein enzymes. As described herein, the molecular significance of this phenomenon was investigated by molecular cloning of p21, and *in vitro* reconstitution of the quaternary cell-cycle kinase complexes. It was discovered that p21, ostensibly as an unphosphorylated or slightly phosphorylated protein, is an inhibitor of each member of the cyclin/CDK family. Phosphorylation of p21 in the quaternary complex appears to overcome this inhibition of kinase activity, allowing the cyclin/cdk/p21/PCNA complex to become activate as a cell-cycle kinase. However, the kinase activity of the activated quaternary complex is still less than the kinase activity of cyclin/cdk binary complexes found in many transformed cells. Furthermore, overexpression of p21 is shown to inhibit the proliferation of mammalian cells.

Northern blot analysis indicates that p21 mRNA is elevated under conditions in which the p53-mediated cell cycle checkpoint pathway is activated. Thus, induction of p21 in response to p53 represents a plausible mechanism for effecting cell cycle arrest in response to DNA damage, and loss of p53 may deregulate growth by loss of the p21 cell cycle inhibitor.

As described in Example 4, a cDNA encoding the p21 component of the quaternary complex was isolated and sequenced (SEQ ID Nos. 5 and 6). p21 was first purified by large scale anti-cyclin D immunoprecipitation, and the purified protein microsequenced. Degenerate PCR primers were prepared based upon the sequences of four peptides. Amplification of cDNA from W138 cells with primers derived from the K10 and K13 peptides (see Example 4) generated a 96 base pair fragment. This was used as a probe to isolate a full-length cDNA from a library prepared from the U118 cell line and several positive clones were obtained. One contained an ~600 base insert which included a 164 amino acid open-reading-frame (see SEQ ID No. 6). *In vitro* translation of this cDNA generated a protein which exactly comigrated with the cyclin D-associated p21 from W138 cells. Partial V8 protease mapping demonstrated that these proteins are identical.

Cyclin/CDK complexes containing p21 were reconstituted using a baculovirus expression system. Quaternary complex formation was observed in lysates from insect cells carrying viruses that encode p21 and PCNA in combination with those encoding cyclin D and CDK4, cyclin E and CDK2, cyclin A and CDK2 or Cyclin B and CDC2. These *in vitro* quaternary complexes precisely reproduce the data above which indicated that p21 and PCNA associate with each of the cyclin kinases *in vivo*. Furthermore, it was observed that p21 alone can bind to each cyclin/CDK pair to form apparent ternary complexes, suggesting

that PCNA is not obligate for the interaction of p21 with cyclins and CDKs. However, the possible presence of insect cell PGNA in the p21/CDK/cyclin complexes cannot be formally excluded.

Employing the same baculovirus reconstitution system to assess the effect of p21 on the enzymatic activity of the cyclin kinases, anti-CDK2 immunoprecipitates were prepared from lysates of  $^{35}\text{S}$ -labelled insect cells coinfectd with viruses encoding CDK2 and cyclin A. The precipitates contained cyclin A/CDK2, and displayed substantial Histone H1 kinase activity. Addition of increasing amounts of a lysate containing p21 resulted in progressive formation of cyclin A/CDK2/21 ternary complexes. As p21 neared stoichiometry, CDK2 kinase activity was abruptly inhibited. Additon of PCNA, in an otherwise identical experiment, resulted in the formation of quaternary complexes but had no effect on either histone kinase activity or its inhibition by p21. Identical inhibition by p21 was observed with cyclin B/CDG2 and cyclin E/CDK2 kinases.

Cyclin D/CDK4 kinase differs from the others in its inability to utilize histone H1 as a substrate. To date, the only substrates known for cyclin D/CDK4 kinases are the members of the RB family of "pocket" proteins (Matsushime et al., *Cell* 71:323-334 (1992)). Therefore, the effect of p21 was tested on the ability of cyclin D/CDK4 to phosphorylated RB. Insect cell lysates containing cyclin D or CDK4 alone showed little activity toward GST-RB. However, cyclin D/CDK4 binary complexes catalyzed substantial RB phosphorylation. Addition of increasing amounts of p21 resulted in the accumulation of cyclin D/CDK4/p21 ternary complexes with a corresponding inhibition of RB phosphorylation. Again, inclusion of PCNA was essentially without effect.

The ability of p21 to inhibit such disparate cyclin/CDK kinases strongly suggests that p21 is a universal CDK inhibitor. Thus, overexpression of p21 *in vivo* would be expected to cause cell cycle arrest. To address this question, the effect of p21 overexpression on cell proliferation was examined using a stable colony formation assay. Transfection of SAOS-2 cells with a pRc-CMV vector alone yielded a large number of stable transformants. However, transfection with either of two independent preparations of a plasmid directing the overexpression of p21 failed to produce an appreciable number of colonies. The effect of p21 overexpression was virtually identical to the effect of p53 overexpression in a parallel transfection. These results support the notion that p21 is an inhibitor of cell proliferation.

As described above, the results obtained with transformed cells indicate that p21 is absent from cyclin/CDK complexes in cells which lack functional p53. Since p53 is known to act as a transcriptional regulator, the ability of p53 to control expression of p21 was examined. Consistent with this expectation, Northern blotting revealed that p21 mRNA was relatively abundant in several normal human fibroblast lines (W138, HS68) but was present

5-10 fold lower levels in fibroblasts transformed by SV40 T-antigen or Li-Fraumeni fibroblasts. Also, p21 expression is suppressed (>10 fold) by expression in normal fibroblasts of oncogenic forms of papillomavirus E6 protein but not in cells expressing non-oncogenic E6 (i.e. low-risk HPV); only oncogenic forms of E6 bind and inactivate p53.

5        Upon treatment of cells with ionizing radiation, p53 levels increase and consequently the abundance of p53 regulated mRNAs becomes elevated (see for example, Kastan et al., *Cell* 7:587-597 (1992)). Thus, enhanced expression of a gene in response to treatment with ionizing radiation is one key hallmark of p53 regulated genes. Therefore, a human myeloid leukemia cell line which was wild-type p53 (ML-1) was treated with five Gray of  $\gamma$ -  
10   irradiation. After four hours, RNA was prepared and analyzed by Northern blotting. This treatment caused an approximate ten-fold elevation in the abundance of the p21 mRNA in comparison to the untreated control. By contrast, similar treatment of another human myeloid leukemia cell line which contains no endogenous p53 (HL-60) failed to cause substantial change in the abundance of p21 mRNA. To formally test whether p21 mRNA is  
15   regulated by the p53 pathway, a murine p21 cDNA was isolated and p21 message levels in fibroblasts derived from p53-null mice were examined. Compared to fibroblasts from normal embryos, fibroblasts from the p53-null mice contained approximately 50-folded lower levels of p21 mRNA. These results indicate that p21 is regulated by the p53 pathway.

      In many transformed cells, cyclin and CDK's associate in binary complexes which  
20   form the core of the cell cycle regulatory machinery. In normal cells, a major fraction of the cyclin kinases acquire two additional subunits and thereby form quaternary complexes. Reconstitution of quaternary complexes in insect cells revealed that p21 is a universal inhibitor of cyclin kinases. As such, p21 inhibits cell cycle progression and cell proliferation upon overexpression in mammalian cells. Taken in conjunction with the previously  
25   demonstrated absence of p21 protein in the cell cycle kinase complexes of cells with deficient p53, these results suggest that p21 could be a transcriptional target of the tumor suppressor protein, p53. One function of p53 is to act in a cellular signaling pathway which causes cell cycle arrest following DNA damage (see for example, Kastan et al. *Cell* 71:587-597(1993)). It is therefore presently suggested that p21 forms a critical link between p53 and the cell cycle  
30   control machinery.

      A further finding of the present invention is directed to the discovery that phosphorylation of p21 (to "pp21"), as part of the quaternary complex, relieves the inhibition of the kinase activity of the complex. Thus, each of the cyclin/cdk/PCNA/p21 containing complexes can, in the normal cell, exist in two forms: inactive (p21) and active (pp21).  
35   However, the kinase activity of the pp21 quaternary complex is not as great as the corresponding cyclin/cdk binary complex (associated with transformed cells), suggesting that

in transformed cells, the binary complex is a superactive kinase and presumably uncoupled (at least as far as p21 is concerned) from p53 suppression. Thus, a differential assay can be used for identifying an agent that inhibits the cyclin/cdk binary complex, but does not inhibit the cyclin/cdk/p21/PCNA quaternary complex. To provide specificity, such inhibitors can  
5 take advantage of, for example, allosteric differences in the cdk induced by the addition of p21 to the cyclin/cdk complex.

#### 10 IV. Cloning of p16, and inhibitor of CDK4

The two-hybrid screening system (Fields et al. *Nature* 340:254 (1989)) was utilized to search for proteins that could interact with human CDK4, and more specifically, to isolate a cDNA encoding p16. Two-hybrid screening relies on reconstituting a functional GAL4  
15 activator from two separated fusion proteins: the GAL4 DNA-binding domain fused to CDK4, GAL4db-CDK4; and the GAL4 activation domain fused to the proteins encoded by HeLa cDNAs, GAL4ad-cDNA. YPB2 was used as the recipient yeast as it is a strain that contains two chromosomal genes under the control of two different GAL4-dependent promoters: HIS3 and LacZ. YPB2 was transformed with a mixture of two plasmids encoding,  
20 respectively, the GAL4db-CDK4 and the GAL4ad-cDNA fusions; several clones were obtained that grew in the absence of histidine and that turned blue in the presence of  $\beta$ -gal. From DNA sequencing data it was determined that each of the positive clones derived from the same gene, although one group represented mRNAs with a shorter 3' end. The sequence of these cDNAs contained, in-phase with the GAL4ad, an open reading frame encoding a  
25 protein of 148 amino acids with a predicted molecular weight of 15,845 daltons (see SEQ ID Nos. 3 and 4). This protein is referred to hereinafter as INK4 (inhibitor of CDK4; see below). The sequence of p16INK4 was compared by standard methods with those present in the currently available data banks and no significant homologies were found.

To test if p16INK4 would specifically bind CDK4, YPB2 were cotransformed with  
30 the GAL4ad-p16INK4 fusion as well as with several target GAL4db fusion constructs containing, respectively, cdc2, CDK2, CDK4, CDK5, PCNA and Snfl (a fission yeast kinase). Transformed cells were plated with and without histidine. Only the GAL4db-CDK4 fusion interacted with GAL4ad-p16INK4 to an extent which allowed growth in the absence of histidine, indicating that this pair of fusion proteins specifically reconstituted a functional  
35 GAL4 activator able to enhance the expression of the HIS3 gene. The same result was



obtained when the ability to transactivate the expression of the  $\beta$ -galactosidase gene was assayed.

The specificity of this interaction was further demonstrated in a cell-free system, by mixing *in vitro* translated ( $^{35}\text{S}$ )-labeled CDKs with a purified bacterially-produced fusion protein consisting of glutathione-S transferase (GST) linked to p16INK4 (17). The GST-p16INK4 fusion was recovered by binding to glutathione-sepharose beads and the association of each CDK was analyzed by gel electrophoresis. Consistent with the previous observations, GST-p16INK4 bound much more efficiently to CDK4 than to cdc2, CDK2 or CDK5.

Since the predicted molecular weight of p16INK4 is close to 16 Kd, the identity of p16INK4 as the CDK4-associated p16 protein found in transformed cell lines (see above) was determined. Two *in vitro* translation products of 15 KD and 17 KD were obtained from the p16INK4 cDNA. These products, as well as the CDK4-associated p16 protein from HeLa cells were treated with N-chlorosuccinimide. The partial NCS-proteolytic pattern of the 17 KD cDNAINK4-derived product was very similar to the pattern obtained with the CDK4-associated p16 protein from HeLa cells, strongly suggesting that the p16INK4 cDNA actually corresponds to p16. Partial digestion with V8 protease of the 17 KD cDNAINK4-derived product and p16 also yielded similar patterns. It is interesting to note that the p16INK4 protein overexpressed in insect cells has an electrophoretic mobility of 15 KD, and its NCS proteolytic map is identical to that obtained with the 15 KD cDNA derived product. This suggests that the actual p16INK4 found in human cells and the 17 KD *in vitro* translation product correspond to posttranslationally modified proteins. The fact that the p16INK4 protein overexpressed in insect cells interacts with CDK4 suggests that this modification is not essential for the interaction (see below).

The identity between p16INK4 and the CDK4-associated protein p16 was further confirmed using antibodies raised against the purified GST-p16INK4 fusion protein. Several human cell lines were used for this experiment: a normal cell line WI38, derived from normal lung fibroblasts; the VA13 cell line derived from WI38 by transformation with the SV40 T-antigen; and HeLa cells. As set out above, anti-CDK4 immunoprecipitates of WI38 revealed the association of CDK4 with cyclin D1, PCNA, p21 and p16. In contrast, in VA13 and HeLa cells CDK4 is only associated with p16. Anti-p16INK4 immunoprecipitates contained a protein with an apparent molecular weight of 16 KD which was readily detectable in the two transformed cell lines, VA13 and HeLa but to a lesser extent in the normal cell line WI38. This protein not only had the same electrophoretic mobility as the p16 protein coimmunoprecipitated with anti-CDK4 serum, but also had an identical NCS partial proteolytic pattern. In addition to p16INK4 a protein of 33Kd was observed in anti-p16 coimmunoprecipitates that was shown to be identical to CDK4 by V8-proteolytic mapping.

Northern analysis of the transcripts present in WI38 and VA13 cells indicated that the p16INK4 mRNA was around many times less abundant in WI38 cells compared to VA13 cells. This difference approximately corresponded to the observed difference in the amount of p16 protein between the two cell lines, suggesting the possibility that p16INK4 expression might be regulated at a transcriptional or post-transcriptional level. Indeed, in three non-virally transformed cell lines the expression of p16INK4 could not be detected even after overexposure of the gel.

To study the biochemical consequences of the interaction of p16INK4 with CDK4, active CDK4-cyclin D complexes have been reconstituted *in vitro* by standard protocols (Kato et al. *Genes Dev* 7:331 (1993); and Ewen et al. *Cell* 73:487 (1993)). The three relevant components, CDK4, p16INK4 and cyclin D1, were expressed in baculovirus-infected insect cells. Extracts were prepared from metabolically (<sup>35</sup>S)-labeled insect cells that separately overexpressed p16INK4, CDK4 or cyclin D1, as well as from cells overexpressing both CDK4 and cyclin D1. In response to increasing amounts of p16INK4, corresponding decreases in the ability of CDK4 to phosphorylate Rb was observed. This inhibition correlated with the association between p16INK4 and CDK4 as detected by immunoprecipitation. No inhibition was observed when CDK2-cyclin D2 complexes were used in a similar assay. To confirm that the inhibition of CDK4 was due to p16INK4, a His-tagged p16INK4 fusion protein (His-p16INK4) was created to have an amino terminal extension of 20 amino acids containing a tract of 6 histidine residues. This fusion protein was overexpressed in baculovirus-infected insect cells, and was purified by virtue of the high-affinity association of the histidine tract to nickel-agarose beads. The His-p16INK4 protein preparation was shown to be >90% pure, and inhibited the activity of the CDK4-cyclin D1 complex under conditions similar to those used for inhibition by the whole lysates.

#### IV. Uses of the Invention

Based on work described herein, it is possible to detect altered complexes of cyclins CDK, PCNA, p21, p19, and p16 in cells obtained from a tissue or biological sample, such as blood, urine, feces, mucous, saliva, or biopsy (including cytological preparations). This has potential for use for diagnostic and prognostic purposes since, for example, there is an apparent link between alteration of a subunit composition of composition of complexes and cellular transformation or abnormal cell proliferation. Diagnostic and therapeutic methods described herein can be used to assess an individual's disease state or probability of developing a condition associated with or otherwise indicated by such rearrangements of complex subunits, and to monitor therapy effectiveness (by assessing the effect of a drug or drugs on subunit rearrangement).

For example, an agent can be developed that recognizes the interactions between CDKs, cyclins, PCNA and low molecular weight polypeptides (such as p21, p19 and p16). The agent can then be contacted with the sample of cells for which the transformation state is to be tested; presence of particular subunits in a complex will be indicative of transformation.

5 For example, a CDK4-p16 complex will be indicative of transformation, as will a cyclin A-p19 complex. Alternatively, agents which recognize different subunits can be used in conjunction, to determine the presence of interactions among the subunits. For example, an agent which recognizes p21 can be used in conjunction with an agent which recognizes a cyclin or a cyclin kinase, to determine whether p21 is complexed with either the cyclin or the  
10 cyclin kinase.

Antibodies specifically reactive with compounds of the quaternary complexes can be produced, using known methods, to be used as agents in these methods. For example, antisera can be produced by injecting an appropriate host (e.g., rabbits, mice, rats, pigs) with the D-type cyclin against which anti sera is desired and withdrawing blood from the host  
15 animal after sufficient time for antibodies to have been formed. Monoclonal antibodies can also be produced using known techniques. Sambrook, J. *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989); Hallow, E. and D. Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Press, New York (1988). Antibodies specifically reactive with CDK5, CDK4 and other CDKs in general,  
20 p21, p19, p16, and cyclins can also be produced using known methods.

In an illustrative embodiment, antibodies are raised against the CDK4/p16 complex. To facilitate the production of such complexes in immunogenic form, the CDK4/p16 complex can be generated by chemical cross-linking. In another embodiment, a CDK4/p16 fusion protein is generated using single chain antibody technology to introduce an  
25 unstructured polypeptide linker region between the polypeptide sequences derived from each of the proteins. This linker can facilitate enhanced flexibility of the fusion protein allowing each subunit to freely interact with the other, reduce steric hindrance between the two fragments, as well as allow appropriate folding of each fragment to occur. The linker can be of natural origin, such as a sequence determined to exist in random coil between two domains  
30 of a protein. Alternatively, the linker can be of synthetic origin. For instance, the sequence (Gly<sub>4</sub>Ser)<sub>3</sub> can be used as a synthetic unstructured linker. Linkers of this type are described in Huston et al. (1988) PNAS 85:4879; and U.S. Patent No. 5,091,513. Thus, immunogenic complexes resembling the CDK4/p16 complex can be generated, and subsequent antibodies isolated which recognize the complex but not the isolated subunits.

35 In another embodiment, antibodies can be raised which recognize unique epitopes of a cyclin/cdk binary complex relative to the p21/PCNA containing quaternary complex. For

instance, each of the binary and quaternary complexes can be chemically cross-linked. By subtractive immunization techniques including neonatal tolerization (Billingham et al. (1953) *Nature* 172:603-606; Golumbeski et al. (1986) *Anal Biochem* 154:373-381; Hasek et al. (1979) *Immunol Rev* 46:3-26; Reading (1982) *J Immunol Methods* 53:261-291; and Streilen et al. (1979) *Immunol Rev* 46:125-146) or chemical immunosuppression (Ahmed et al. (1984) *J Am Acad Dermatol* 11:1115-1126; Matthew et al. (1983) *CSH Symp Quant Biol* 48:625-631; Matthew et al. (1987) *J Immunol Methods* 100:73-82; and Turk et al. (1972) *Immunology* 23:493-501), a host animal can be rendered tolerant for epitopes on the quaternary complex. Subsequent immunization with the corresponding binary complex will allow production of antibodies which are specific for "rare" epitopes of the cyclin/cdk complex, that is, epitopes unique to the binary complex. Such antibodies can be used to detect cellular transformation by virtue of their ability to distinguish the binary complex from the quaternary complex.

In yet another embodiment, the present invention particularly contemplates assays and kits for detecting p16 levels in cells. Antibodies specific for p16 (as described herein), or nucleic acid probes directed to detecting mRNA levels of p16 transcripts, can be used to detect transformed cells. As described above, the level of p16 mRNA, and presumably p16 protein, is elevated in transformed cells relative to normal cells. Thus, detecting the level of p16 gene expression is diagnostically useful in determining the presence of transformed cells. In an illustrative embodiment, *in situ* hybridization assays can be performed using nucleic acid probes directed to p16 sequences and generated by standard protocols (see, for example, the Taub et al. U.S. Patent No. 4,820,630; Falkow et al. U.S. Patent No. 4,358,935; and the Bresser et al. U.S. Patent No. 5,225,326).

A preferred assay of the present invention allows quantitative differences to be ascertained in p16 levels between transformed which a characterized by p16/CDK4 complexes, and untransformed cells. Briefly, cells, either as single cell suspensions or as tissue slices may be deposited on solid supports such as glass slides. Alternatively, cells are placed into a single cell suspension of about  $10^5$  - $10^6$  cells per ml. The cells are fixed by choosing a fixative which provides the best spatial resolution of the cells and the optimal hybridization efficiency when nucleic acid probes are employed, or the optimal binding affinity and specificity when anti-p16 Abs are utilized.

In the instance of nucleic acid probes, the hybridization can then carried out in the same solution which effects fixation. This solution contains both a fixative and a chaotropic agent such as formamide. Also included in this solution is a hybrid stabilizing agent such as concentrated lithium chloride or ammonium acetate solution, a buffer, low molecular weight DNA and/or ribosomal RNA (sized to 50 bases) to diminish non-specific binding, and a pore

forming agent to facilitate probe entry into the cells. Nuclease inhibitors such as vanadyl ribonucleoside complexes may also be included.

To the hybridization solution is added the p16 probe, to hybridize with a target polynucleotide. The most preferable probe is a single-stranded anti-sense probe. For hybridization to cellular mRNA, a probe of approximately 75 to 150 bases in length is used. The hybridization solution containing the probe is added in an amount sufficient to cover the cells when using immobilized cells. The cells are then incubated at a optimal temperature.

The probes may be detectably labeled prior to the hybridization reaction. Alternatively, a detectable label may be selected which binds to the hybridization product. Probes may be labeled with any detectable group for use in practicing the invention. Such detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and in general most any label useful in such methods can be applied to the present invention. Particularly useful are enzymatically active groups, such as enzymes (see *Clin. Chem.*, 22:1243 (1976)), enzyme substrates (see British Pat. Spec. 1,548,741), coenzymes (see U.S. Pat. Nos. 4,230,797 and 4,238,565) and enzyme inhibitors (see U.S. Pat. No. 4,134,792); fluorescent markers (see *Clin. Chem.*, 25:353 (1979); chromophores; luminescent compounds such as chemiluminescent and bioluminescent markers (see *Clin. Chem.*, 25:512 (1979)); specifically bindable ligands; proximal interacting pairs; and radioisotopes such as  $^3\text{H}$ ,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,  $^{125}\text{I}$  and  $^{14}\text{C}$ .

In similar fashion, anti-p16 antibodies can be labeled and used to detect the presence of p16 protein in samples of cells.

The present invention provides an assay system for detecting inhibitors of cyclin/cdk complexes of transformed cells. For example, a cyclin D and a cdk (i.e. cdk2, cdk4, or cdk5) can be provided under conditions wherein the complex is substantially free of other proteins normally present with the complex in a transformed cell in which it "normally" occurs. The complex is contacted with a substrate such as the H1 histone, Rb, p107, or the like, in the presence and absence of a potential inhibitor. Comparing the level of the phosphorylation of the kinase substrate allows detection of agents able to inhibit the kinase function.

Likewise, the present invention also provides a method for screening potential inhibitors of a particular quaternary complex. For example, as described herein, complexes comprising a predetermined cyclin and cdk, as well as p21 and (though optionally) PCNA, can be provided under conditions wherein the complex is substantially free of other proteins normally present with the complex in a cell in which it naturally occurs. For instance, the complex can be reconstituted from semi-purified or purified proteins, or from lysates of cells in which the complex is not naturally present.

In similar fashion, an assay comprising binary complex (cyclin/cdk) and an assay comprising its corresponding p21-containing complex (under activating conditions) can be run side by side to identify agents able to inhibit the binary complex but which do not inhibit (to the same extent) the p21-containing complex.

5 In yet a further embodiment, the complex can be provided in another cell which ordinarily lacks such a complex. For example, both a human cyclin and cdk (i.e. cyclin D and cdk4) can be used to replace a yeast cyclin and cdc/cln (see, for example, PCT Application No. Application No. PCT/US92/04146) in a deficient strain. Thus, the human cyclin/cdk binary complex functions in the cell-cycle of the yeast. Introduction of p21 can  
10 result in the formation of a cyclin/cdk/p21 complex and, in the absence of a kinase able to phosphorylate p21, inhibition of the human cell-cycle kinase and the concomitant inhibition of proliferation of the yeast cell. Such a cell can be then used to easily screen a cDNA library for a kinase able to relieve inhibition of the p21-containing complex by phosphorylating p21. Identification of the p21-kinase allows subsequent development of inhibitors which prevent  
15 formation of pp21, and therefore are useful anti-proliferative agents.

The present invention also includes a method of screening compounds or molecules for their ability to inhibit or suppress the transformation of a cell. A compound or molecule to be assessed for its ability to inhibit transformation is contacted with the cells, under conditions appropriate for entry of the compound or molecule into the cells. Transformation  
20 of the cell will result in selective rearrangement of subunits in the cyclin complexes. Comparison of the rate or extent of rearrangement in the presence of the compound or molecule being assessed with that of an appropriate control (e.g., the same type of cells without added test drug) will demonstrate the ability or inability of the compound or molecule to inhibit subunit rearrangement. Drugs which inhibit subunit rearrangement are  
25 also the subject of this invention.

For example, protein kinase-D type cyclin complex formation can be prevented in a direct manner by, for example, introducing into cells a drug or other agent which binds the protein kinase or the D-type cyclin or otherwise interferes with the physical association between the cyclin and the protein kinase it activates (e.g., by intercalation) or disrupts the  
30 catalytic activity of the enzyme. This can be effected by means of antibodies which bind the kinase or the cyclin or a peptide or low molecular weight organic compound which, like the endogenous D-type cyclin, binds the protein kinase, but whose binding does not result in activation of the enzyme or results in its being disabled or degraded. Peptides and small organic compounds to be used for this purpose can be designed, based on analysis of the  
35 amino acid sequences of D-type cyclins, to include residues necessary for binding and to exclude residues whose presence results in activation. This can be done, for example, by

systematically mapping the binding site(s) and designing molecules which recognize or otherwise associate with the site(s) necessary for activation, but do not cause activation. As described herein, there is differential expression in tissues of D-type cyclins, as well as the complexes formed with CDKs. Thus, it is possible to selectively decrease mitotic capability of cells by the use of an agent (e.g., an antibody or anti-sense or other nucleic acid molecule) which is designed to interfere with (inhibit) the activity and/or level of a complex comprising a particular D type cyclin and CDK. For example, in treating tumors involving the central nervous system or other non-hematopoietic tissues, agents which selectively inhibit cyclin D1 might be expected to be particularly useful, since D1 has been shown to be differentially expressed (expressed at particularly high levels in cells of neural origin).

Formation of complexes of D-type cyclin, CDK, PCNA and p21 can also be prevented in a similar manner as that described above for inhibiting CDK/D-type cyclin complex formation. That is, complex formation can be prevented directly (e.g., by means of a drug or agent which binds a component of the complex or otherwise interferes with the physical association of complex components. Complex formation can also be prevented in an indirect manner, such as by preventing transcription and/or translation of DNA and/or RNA encoding a component of the complex, in a similar manner to that described above for blocking D-type cyclin-protein kinase complex formation. Alternatively, complex formation can be prevented indirectly by degrading one or more of its constituents.

For example, a drug which selectively inhibits the ability of cyclin D2 or cyclin D3 to form a quaternary complex can be used. Each of the other complex constituents is also a target whose function or availability for complex formation can be altered. For example, CDK2, CDK4, CDK5 and other cyclin dependent kinases which complex with a D-type cyclin can be inhibited or enhanced, either in terms of their function or their availability for incorporation into the quaternary complex. Drugs or agents which alter PCNA function or availability, or which alter p21 function or availability, or p16 function or availability can also be used to inhibit or enhance cell division. In the case of each quaternary complex constituent, it is possible to introduce into cells an agent, such as a small peptide or other organic molecule, which mimics the complex constituent in terms of binding but lacks its active region(s), which results in formation of complexes lacking the activity or interactions of the normally-produced complex.

Direct inhibition of complex formation can also be nonspecific (i.e., can affect the majority of cells or all cells in which the D-type cyclin-containing quaternary complex is formed). This can be done, for example, by introducing into cells a drug which inhibits function or availability of a common component of the quaternary complex (e.g., PCNA) or by introducing a mixture or cocktail of drugs, which together inhibit all D-type cyclins.

Alternatively, indirect inhibition of quaternary complex is possible. That is, a drug or agent which acts to cause less of a complex constituent (e.g., D-type cyclin, CDK, PCNA or p21) available can be used. Such drugs or agents include those, such as anti-sense oligonucleotides, which block transcription or translation and those, such as an enzyme, which degrade complex constituents, either prior to or after their incorporation into a quaternary complex.

Drugs or agents useful in the present method of altering, particularly inhibiting, cell cycle start and, thus, cell division, can be existing compounds or molecules (e.g., small organic molecules, anti-sense oligonucleotides, and inorganic substances) or materials designed for use in the present method. In either case, such drugs can be identified by the method of the present invention.

In a particular embodiment of the present invention, interaction trap assays can be used to identify agents able to disrupt complex formations with cyclins, particularly D-type cyclins, as well as p16/CDK4 complexes. For instance, two hybrid assays described above can be utilized in such assays. In an illustrative embodiment, GAL4 activator fusion construct as described herein containing CDK4 and p16 are used to measure the ability of a candidate agent to disrupt the formation of CDK4/p16 complexes. Cells transfected with each of the constructs are contacted with a candidate agent, and the level of expression of a reporter gene (such as  $\beta$ -galactosidase, as above) is detected. A decrease in expression can be indicative of an inhibitor of the complex.

Furthermore, a three hybrid assay can be preformed to detect inhibitors of CDK4/p16 which do not inhibit CDK/cyclin complexes. For example, constructs can be generated in which p16 and a D-type cyclin each are part of fusion proteins which constitute the DNA binding domains of discrete proteins recognizing different DNA sequences. CDK4 is then generated as fusion protein with an activating domain, such its interaction with the p16 fusion protein results in expression of one reporter gene, while its interaction with the cyclin D fusion protein drives expression of different reporter gene. For instance, the p16 fusion protein can drive expression of a luciferase gene, while the cyclin D construt provides expression of a drug-resistance marker. Thus, in the presence of an agent which inhibits p16/CDK4 interactions, the expression of the drug resistance marker indicates that cyclin D/CDK4 complexes are not disrupted.

Moreover, given the inhibitory ability of p16, the present invention further contemplates the use of such knowledge to generate peptidomimetic analogs of particular portions of p16, which can be used as anti-proliferative agents. The CDK4 binding interactions with p16 can be easily ascertained, such as by use of mutagenesis and the above



described interaction trap assay. Likewise, peptide fragments derived from p16 can be assayed for their ability to disrupt CDK4/cyclin complexes as described above.

Once an appropriate drug or agent has been identified, it can be administered to an individual, particularly a human or other vertebrate, by any route effective in introducing the drug or agent into cells in sufficient quantity to have the desired effect (i.e., alteration of cell division). For example, a selected drug can be administered intravenously, intramuscularly, by direct injection into a tumor, via the gastrointestinal tract (e.g., orally), intraperitoneally or intranasally. In some cases, ex vivo administration is appropriate (e.g., in instances where blood or bone marrow is removed from the body, treated and returned to the body).

Generally, the drug or agent used to alter cell division will be included in a formulation which can also include a physiological carrier (e.g., a buffer or physiological saline), stabilizers, an adjuvant, and flavoring agents. The quantity of the drug to be administered can be determined empirically and will vary depending on considerations such as the age, weight and height of the recipient and the severity of the condition to be treated.

Antibodies specifically reactive with D-type cyclins of the present invention can also be produced, using known methods. For example, anti-D type cyclin antisera can be produced by injecting an appropriate host (e.g., rabbits, mice, rats, pigs) with the D-type cyclin against which anti sera is desired and withdrawing blood from the host animal after sufficient time for antibodies to have been formed. Monoclonal antibodies can also be produced using known techniques. Sambrook, J. et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989); Hallow, E. and D. Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Press, New York (1988). Antibodies specifically reactive with CDK5, can also be produced using known methods.

The present invention also includes a method of screening compounds or molecules for their ability to inhibit or suppress the function of a cyclin, particularly a D-type cyclin. For example, mutant cells as described herein, in which a D-type cyclin such as D1 or D3, is expressed, can be used. A compound or molecule to be assessed for its ability to inhibit a D-type cyclin is contacted with the cells, under conditions appropriate for entry of the compound or molecule into the cells. Inhibition of the cyclin will result in arrest of the cells or a reduced rate of cell division. Comparison of the rate or extent of cell division in the presence of the compound or molecule being assessed with cell division of an appropriate control (e.g., the same type of cells without added test drug) will demonstrate the ability or inability of the compound or molecule to inhibit the cyclin. Existing compounds or molecules (e.g., those present in a fermentation broth or a chemical "library") or those developed to inhibit the cyclin activation of its protein kinase can be screened for their

effectiveness using this method. Drugs which inhibit D-type cyclin are also the subject of this invention.

5 The present invention also includes a method of screening compounds or molecules for their ability to alter formation of the quaternary complex described herein. This method is carried out in much the same way as the method, described above, for identifying compounds or molecules which inhibit a D-type cyclin. In the subject method, the compound or molecule to be tested and cells in which D-type cyclin-containing complex is formed are combined, under conditions appropriate for complex formation to occur and entry into cells of the compound or molecule being tested. Complex formation can be determined, as  
10 described herein. Inhibition of a complex constituent or of complex formation will result in arrest of the cells or a reduced rate of cell division. Comparison of the rate or extent of cell division in the presence of the compound or molecule being tested with the rate or extent in the absence of the compound or molecule will demonstrate whether it has an effect on cell division (i.e., division to a lesser extent in the presence of the compound or molecule tested  
15 than in its absence is an indication the compound or molecule is an inhibitor). Drugs or agents which inhibit complex formation and, as a result, cell division, are also the subject of this invention.

20 The present invention will now be illustrated by the following examples, which are not intended to be limiting in any way.

#### EXAMPLE I

25 *Demonstration that D-Type Cyclins Associated with Multiple Protein Kinases and the DNA Replication and Repair Factor PCNA*

##### *(i) Experimental Procedures*

##### *Cells*

30 Human diploid lung fibroblast WI38 cells were obtained from American Type Culture Collection at passage 13 and were grown in Dulbecco-Modified Eagle media supplemented with 10% fetal bovine serum and used between passages 16-22. 293 cells were cultured similarly.

##### 35 *Antibodies*

To raise anti-cyclin D1 antibody, a 609 bp DNA restriction fragment encoding 202 amino acid residues (~25 kDa) of human cyclin D1 amino-terminal region (the NCoI

fragment from nucleotides 143 to 751 in Figure 2 of Xiong, *et al.*, *Cell* 65:691-699 (1991 and *Current Biology* 1:362-364 (1991)) was subcloned into a phage T7 expression vector, pET-3d (Studier, *et al.*, *Methods in Enzymology*, 185:60-89 (1990)) and introduced into *E. coli* strain BL21 (DE3). Bacterial extracts were prepared in lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH7.5 and 10% glycerol) by disrupting cells with sonication and clarifying the supernatant by centrifugation at 20,000 g for 10 minutes. Pellets containing insoluble cyclin D protein was resuspended in lysis buffer supplemented with 8 M urea, after 30 minutes shaking at room temperature, the suspension was centrifuged again at 20,000 g for 10 minutes. Pellets containing insoluble cyclin D protein was resuspended in SDS sample buffer and separated on 10% SDS-polyacrylamide gel. The 25 kDa cyclin D protein was visualized and excised after staining the gel with 0.25M KCl in the cold room. Gel slices were further crushed by repeated passage through an 18 gauge needle and cyclin D protein was extracted by incubating the crushed gel particles with PBS containing 0.1% SDS at 42°C for several hours and used for injection of rabbits. To affinity purify the anti-cyclin D1 immunoglobulins, bacterially produced p25 proteins were cross-linked to the Reacti-Gel (6X) according to the manufacturer's instruction. The affinity column was washed with excess volume of PBS containing 0.05% Tween-20 before and after crude serum was applied to the column. Bound immunoglobulins were eluted with Glycine-NaCl (pH2.5) into 1.5 M Tris-HCl, pH8.5 to instantly neutralize the antibodies. To reduce the high background caused by immunoglobulin proteins, affinity purified anti-cyclin D1 was crosslinked to protein A agarose beads according to Harlow and Lane, *Antibodies: a laboratory manual*, Cold Spring Harbor Laboratory Press, NY (1988). On Western blots, the anti-cyclin D1 antiserum weakly cross-reacts with bacterially produced human cyclin D2, very poorly with bacterially produced human cyclin D3, and detects a single band from total WI38 cell lysates. In the immunoprecipitations with RIPA buffer (0.1% SDS), more than 90% of cyclin D1-associated p36, p33, p31 and p21 are disappeared while the amount of cyclin D1 remained to be the same as that in the immunoprecipitations with NP40 (0.5%) buffers.

For anti-CDK5 antibody production a peptide CYFSDFCPP, with the underlined amino acid residues corresponding to the carboxy-terminal region of CDK5, was synthesized. The peptide was coupled to keyhole limpet hemocyanin (Pierce) which was then used to immunize rabbits by standard protocols (Green, *et al.*, *Cell* 28:477-487 (1982)).

Anti-cyclin D3 peptide antibody was similarly raised against a synthetic peptide CDELQASTPTDVRDIDL, with the underlined region corresponding to the carboxy-terminal region of human cyclin D3. The rabbit was later stimulated with bacterial produced full length human cyclin D3. Cyclin D3 specific immunoglobulins were purified on an affinity column in which the 17-mer cyclin D3 peptides were crosslinked to the Reacti-Gel

(6X). The affinity purified anti-cyclin D3 peptide antibody does not cross-react with bacterially produced cyclin D1 or D2 on Western blots and does not immunoprecipitate cyclin D1 from W138 cell lysates.

The antiserum against *S. pombe* p34<sup>cdc2</sup> (G8) was described before (Draetta, *et al.*, *Cell* 50:319-325 (1987)). Human auto-immune anti-PCNA antiserum are generally known. Affinity purified anti-PCNA monoclonal antibody used in Western-blots was purchased from Boehringer Mannheim. Affinity purified anti-PCNA monoclonal antibody used in immunoprecipitation was purchased from Oncogene Science. Anti-CDK2 peptide antiserum was previously described (Pagno, *et al.*, *EMBO J* 11:961-971 (1992)) and does not cross-react with CDC2, CDK4 and CDK5 polypeptides. Anti-CDK4 antiserum was raised against a fusion protein of glutathione S transferase (GST) and a C-terminal portion of CDK4. It does not cross-react with CDK2 and CDK5.

(ii) *Screening Human cDNA Expression Library*

A human HeLa cell cDNA expression library constructed in lambda ZAP II (#936201) was from Stratagene. Human p34<sup>cdc2</sup> was highly insoluble when produced from bacteria. The conventional antibody screening method (Young and Davis, *Proc. Natl. Acad. Sci.* 80:1194-1198 (1983)) is suitable only when there is sufficient amount of soluble recombinant proteins in phage plaques. The screening method, therefore, was modified to include a step which involved the use of 6M guanidine to solubilize recombinant proteins after they have been transferred to nitrocellulose paper, a procedure which was initially developed to produce refolded recombinant proteins with certain activities (Vinson, *et al.*, *Gene Dev.* 2:801-806 (1988)). Two million phage plaques from the  $\lambda$ ZAP II HeLa cDNA library were screened with antiserum against *S. pombe* p34<sup>cdc2</sup> (G8). After overlaying phage plaques with IPTG-impregnated nitrocellulose filters for 4 hours at 42°C, the filters were removed from culture dishes and were then treated with 6 M guanidine-HCl in a buffer containing 25 mM Hepes, pH7.0, 50 mM NaCl, 2 mM DTT for 10 min at 25°C. The filters were washed free of guanidine with Tris-buffered saline before antibody incubation. This procedure enhanced our antibody detection signal greatly which probably was due to the solubilization of bacterial-produced polypeptide precipitates by guanidine. The G8-positive cDNA clones subcloned into pBluescript SK vector (Stratagene) and sequenced from both directions using ABI automated DNA sequencer (Model 373A). For sequence homology search, the FASTA program was used (Pearson and Lipman, *Proc. Natl. Acad. Sci.* 85:2444-2448 (1988)).

(iii) *Immunoprecipitation and Western-Blotting*

For metabolic labelling with [ $^{35}\text{S}$ ] methionine, sub-confluent (40-60%) cells were washed twice with prewarmed labelling media (methionine-, cystine-free DMEM [ICN] supplemented with 10% dialyzed fetal bovine serum, [GIBCO]). After 30 minutes incubation with the labelling media, [ $^{35}\text{S}$ ] methionine (Trans $^{35}\text{S}$ -label, ICN) was added to media (approximately 200  $\mu\text{Ci/ml}$ ) and continued to incubate for four to six hours before lysis. All steps of immunoprecipitations were carried out in the cold room. Cells from 40 to 60% confluent 150 mM dish were washed twice with cold PBS and scraped into NP-40 lysis buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 20 mM EDTA, 0.5% NP-40, 1mM PMSF, 25  $\mu\text{g/ml}$  leupeptin, 25  $\mu\text{g/ml}$  aprotinin, 1 mM benzamidine and 10  $\mu\text{g/ml}$  trypsin inhibitor) and lysed by rotating for 15 to 30 minutes. Nuclei were removed by centrifugation at 15,000 g for 5 minutes and lysates were pre-cleared by incubating with either pre-immune serum or normal rabbit serum and IgG sorb (The Enzyme Center, Inc.) for 20 to 30 minutes followed by a 10 minute centrifugation at 15,000 g. Antibody pre-coupled to the protein A agarose beads (Pierce) was added to the clarified lysates and incubated for six to eight hours. Immunoprecipitates were washed three to four times with lysis buffer at room temperature, resuspended in SDS sample buffer and separated on SDS-polyacrylamide gels.

For the  $^{35}\text{S}$  methionine-labelled precipitates, polyacrylamide gels (except those for V8 proteolytic mapping experiments) were fixed with 10% glacial acetic acid and 30% methanol for 30 minutes to one hour, enhanced by impregnating with autoradiography enhances (Du Pont) for 30 minutes and precipitated in water for 15 to 30 minutes. Enhanced gels were dried and exposed to X-ray films at  $-70^{\circ}\text{C}$ . For Western-blotting, polypeptides were transferred to a nitrocellulose filter using a SDE Electroblothing System (Millipore) for 45 minutes at constant current of 400 mA. The filter was blocked for 1 to 3 hours with TBST (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 0.1% Tween-20) containing 5% dry milk, incubated with primary antibody for 4 hours to overnight in TBST containing 5% dry milk and washed 4 times, 10 minutes each time, with TBST. Appropriate secondary antibody (1:10,000 dilution of either horseradish peroxidase linked sheat anti-mouse Ig or donkey anti-rabbit Ig, Amersham) were incubated with filters for one hour and specific proteins were detected using an enhanced chemiluminescence system (ECL, Amersham).

30

#### (iv) *Partial Proteolytic Peptide Mapping*

Human cyclin D1, cyclin D2, cyclin D3, CDC2, CDK2, CDK3, CDK4, CDK5 and PCNA were subcloned into pBluescript vector (Stratagene) for *in vitro* translation with T7 RNA polymerase using a TNT coupled reticulocyte lysate system (Promega). Immunoprecipitation of [ $^{35}\text{S}$ ] methionine-labelled lysates and SDS-polyacrylamide gel electrophoresis were the same as described above. Polyacrylamide gels were dried without

35

prior fixation and enhanced treatment, exposed to Fuji image plates and visualized on Fuji bio-imaging analyzer BAS2000. Appropriate protein bands were excised from the gels using image printout as template, in-gel partially digested with various amount of S. aureus V8 protease according to (Cleveland, *et al.*, *J. Biol. Chem.* 252:1102-1106 (1977)) and (Harlow and Lane, *Antibodies: a laboratory manual*, Cold Spring Harbor Laboratory Press, NY (1988)), separated on a 17.5% SDS-PAGE. Gels were dried and exposed to a X-ray film for 2 weeks, or analyzed on a Fuji image analyzer BAS2000.

## EXAMPLE 2

### *Demonstration of Selective Subunit Rearrangement of Cell Cycle Complexes In Association With Cellular Transformation by a DNA Tumor Virus or Its Oncogenic Product*

#### *(i) Cellular Transformation With DNA Tumor Virus SV40 Is Associated With Subunits Rearrangement of Cell Cycle Complexes*

Preparation of [<sup>35</sup>S] methionine-labelled cell lysates and polyacrylamide gel electrophoresis were as described above, as well as described in PCT Publication No. WO92/20796. Cell lysates were prepared from either human normal diploid fibroblast cells WI38 or DNA tumor virus SV40 transformed WI38 cells, VA13. Cell lysates were immunoprecipitated with antibodies against each cell cycle gene products.

#### *(ii) Subunit Rearrangements of Cell Cycle Complexes In Two Different Pair Cell Lines*

Methods for preparation of cell lysates are the same as described above. Two different pair cell lines were used in these experiments. HSF43 is a normal human diploid fibroblast cell line and CT10 (full name CT10-2C-T1) is a derivative of HSF43 transformed by SV40 large tumor antigen. CV-1 is an African green monkey kidney cell line and COS-1 is a derivative of CV-1 transformed by SV40.

#### *(iii) Cellular Transformation by DNA Tumor Virus SV40 Is Associated With Rearrangement of PCNA Subunit of Cell Cycle Complexes*

Preparation of cell lysate, electrophoresis, and Western blotting conditions are the same as described above. Normal human diploid fibroblast cell lines and their SV40 transformed cell lines are described above. Immunoprecipitates derived from each antibody were separated on polyacrylamide gels and blotted with anti-PCNA antibody.

#### *(iv) Cellular Transformation by DNA Tumor Virus SV40 Is Associated With Rearrangement of CDK4 Subunit of Cell Cycle Complexes*

Preparation of cell lysate, electrophoresis, and Western blotting conditions are the same as previously described. Normal human diploid fibroblast cell lines and their SV40 transformed cell lines are described above. Immunoprecipitates derived from each antibody were separated on polyacrylamide gels and blotted with anti-CDK4 antibody.

Example 3  
*Cloning of p16<sup>INK4</sup>, an inhibitor of CDK4 activity*

(i) *Cloning of p16<sup>INK4</sup> using the two hybrid assay*

5        *Saccharomyces cerevisiae* YPB2 cells were transformed simultaneously with a plasmid containing a GAL4db-p16INK4 fusion and with a plasmid containing, respectively, the GAL4ad fused to cdc2 (CDK1), CDK2, CDK4, CDK5, PCNA (proliferating cell nuclear antigen), and the fission yeast kinase Snf 1. After growing cells in medium selective for both plasmids (minus tryptophan and minus leucine), two colonies were picked randomly and  
10        were streaked in plates that either contained or lacked histidine. The ability to grow in the absence of histidine depends on the expression of the HIS3 gene that is under a GAL4-responsive promoter and, therefore, indicates that a functional GAL4 activator has been reconstituted through the interaction of p16INK4 with the corresponding target protein.

15        (ii) *Interaction of p16<sup>INK4</sup> CDKs*

      Purified bacterially-produced GSTp16INK4 fusion protein was mixed with (<sup>35</sup>S)-labeled *in vitro* translated cdc2, CDK2, CDK4 and CDK5. Mixtures contained 0.5 µg of purified GST-p16INK4 and an equivalent amount of *in vitro* translated protein (between 0.5 to 5 µl; TNT Promega) in a final volume of 200 µl of a buffer containing 50 mM Tris-HCl  
20        pH 8, 120 mM NaCl and 0.5% Nonidet P-40. After 1 h at 4°C, 15 µl of glutathione-agarose beads were added and incubation was resumed for an additional hour. Beads were recovered by centrifugation, washed 4 times with the incubation buffer, and mixed with standard protein-gel loading buffer. Samples were loaded into a 15% poly-acrylamide gel and (<sup>35</sup>S)-labeled proteins were detected by fluorography. The GSTp16INK4 fusion protein was  
25        overexpressed in the pGEX-KG vector and purified by standard techniques. The *in vitro* translation templates were derived from the pBluescript vector (Stratagene).

(iii) *Proteolytic mapping of p16<sup>INK4</sup>*

      The *in vitro* translated (<sup>35</sup>S)-labeled p16INK4 (TNT Promega) was obtained using  
30        the p16INK4 cDNA cloned into pBluescript vector (Stratagene) as a template, and the CDK4-associated p16 protein was co-immunoprecipitated with an anti-CDK4 serum from metabolically (<sup>35</sup>S)-labeled HeLa cells lysates. Partial proteolysis was done over the corresponding gel slices after extensive equilibration in a buffer and digestion was accomplished by addition of NCS at different concentrations. The products were run in a  
35        17.5% polyacrilamide gel and detected in a phosphoimager Fujix 2000.



(iv) *Detecting the effects of p16<sup>INK4</sup> on CDK4-cyclin D complexes*

Baculovirus-infected insect cells overexpressing p16<sup>INK4</sup>, CDK4, cyclin D1, or both CDK4 and cyclin D1 together were metabolically (<sup>35</sup>S)-labeled. The different incubation mixtures were composed by extracts containing p16<sup>INK4</sup>, CDK4, cyclin D1 and both CDK4 and cyclin D1, and were immunoprecipitated with anti-p16<sup>INK4</sup> serum, anti-CDK4 serum without any previous preincubation, and anti-CDK serum preincubated with the peptide originally used to raise the antiserum and anti-cyclin D1 serum. Immunoprecipitates were then analyzed by SDS-PAGE.

EXAMPLE 4

*p21 is a Universal Inhibitor of the Cyclin Kinases and a Potential Effector of the p53 Checkpoint Pathway*

(i) *Sequence of the p21 cDNA*

The sequence of the p21 cDNA and the deduced amino acid sequence of the p21 protein are given in SEQ ID Nos. 5 and 6. For the purification of p21, W138 cells (passage 24) were grown to late log phase of 400, 15 cm tissue culture dishes in DMEM supplemented with 10% fetal bovine serum. All subsequent steps were carried out at 4°C. Cells were rinsed in PBS, harvested and lysed in NP-40 lysis buffer. The lysate was clarified by centrifugation at 5000xg for 10 minutes and the supernatant was added to 2.5 mg of affinity purified cyclin D1 antibodies, covalently crosslinked to protein A sepharose beads with dimethylpalmitate (Pierce). Immunoprecipitation was carried out for four hours after which the beads were washed four times with lysis buffer. The supernatant was subjected to a second round of affinity chromatography by the addition of fresh anti-cyclin D1 sepharose. Proteins were released from the beads by boiling in SDS sample buffer and loaded onto a 12% SDS-polyacrylamide gel (acrylamide:bis 37.6:1). In this gel system, the relative mobility of PCNA and cyclin D1 are reversed with respect to the gel system used previously (acrylamide:bis 117:1). The gel was stained with 0.05% Coomassie Brilliant Blue G (sigma) for 15 minutes, destained and soaked in water for one hour. The p21 protein (~2 µg) was excised from the gel and subjected to In-gel digestion with Achromobacter endoprotease I for 24 hours at 30°C as previously described (Kawasaki et al., *Anal. Biochem.* 191:332-336 (1990)). Digests were cleared by centrifugation and the supernatant was filtered through a 0.22 micron membrane (Ultrafree-MC, milipore). Peptides were separated by reverse-phase HPLC (Hewlett Packard 1090) using a Vydac C18 column (2.1x250 mm, 5 µm, 300A) with an anion exchange pre-column (Brownlee GAX-013, 3.2x15 mm). Peptides were eluted with an acetonitrile gradient and their absorbance was monitored at 214, 280, 295 and 550 nm. Amino acid sequence was performed on an automated microsequencer (ABI model 470) with

on-line HPLC (ABI model 120A) analysis of PTH-amino acids. Four peptide sequences were obtained as follows: K10, tSLVP?SGEQAEGSPsk; K13, ?RQTSMTDFYHSK; K14, RRLIFSK; K21, LYLPTGPpRSRDEDLGIS (lower case and question marks indicate uncertainty).

5

Degenerate oligonucleotide primers were designed based upon the three longest peptides, K10, K13 and K21. Primers were synthesized in both directions and codons for serine were split to reduce degeneracy. One or two amino acids were reserved at each end for the verification of any PCR product. Template DNA was prepared from several human  
10 cDNA libraries (W138 and HeLa cell, Stratagene; U118 cell, a gift of Dr. M. Wigler, CSHL). Thirty-five cycles of amplification were performed (50°C or 55°C annealing and 72°C extension) after which products were resolved on a 1.5% agarose gel. All DNA fragments smaller than 500 bases were excised and inserted into pUC118 for sequence analysis. Amplification with one pair of primers derived from the K10 and K13 peptides (K10 primer  
15 GGNGA[A/G]CA[A/G]GCN GGNTCNCC, encoding GEQAEGSP; K13 primer TTNCA[A/G]TG[A/G]TA[A/G]AA[A/G]TCNGTCATNCANGT[C/T]TG, encoding QTSMTDFYHSK) gave rise to a specific 96 bp PCR fragment that encoded 13 amino acids in addition to those encoded by the PCR primers. This sequence encoded KRR preceeding the K13 primer. This was consistent with the sequence K?R which was predicted to preceed  
20 the sequence encoded by the K13 primer. The PCR fragment was excised from pUC118 and used as a probe to screen a human U118 cDNA library. A number of positives were obtained and ten were chosen for subsequent analysis. One of these contained an ~600 base insert carrying the entire p21 coding region. Comparison with published sequences revealed that this protein is identical to the previously described SDI protein (Smith, International  
25 Publication No. WO 93/12251).

*(ii) Reconstruction of p21/PCNA/cyclin/CDK quaternary complexes in baculovirus infected cells*

Exponentially growing Sf9 cells were co-infected with baculoviruses encoding p21, a  
30 cyclin, and a CDK in the presence or absence of a baculovirus directing the expression of PCNA. At 40 hours post-infection, cells were labelled with [<sup>35</sup>S] methionine for 3 hours and lysed in NP40 lysis buffer. The protein complexes were immunoprecipitated with anti-CDK4, anti-CDK2, or anti-CDC2 antibodies and analyzed by gel electrophoresis. The positions of protein molecular weight standards are indicated.

35 Briefly, insect Sf9 cells were maintained in Grace's medium supplemented with 10% heat-inactivated fetal bovine serum, lactalbumin hydrolysate, and yeastolate ultrafiltrate at

27°C. Recombinant baculoviruses were constructed using the BACULOGOLD transfection system (Pharmingen, San Diego, CA) according to the manufacturers instructions. For the production of recombinant proteins, Sf9 cells were infected with multiplicities of infection above 10. After 36-48 hours, the cells were labelled with 100 µCi/ml of [<sup>35</sup>S]-methionine (New England Nuclear) for 3 hours.

(iii) *p21 is an inhibitor of cyclin A/CDK2 kinase*

Aliquots of an Sf9 cell lysate that contained both cyclin A and CDK2 were mixed with varying amounts of a p21-containing lysate, with certain of the aliquots having an additional amount of a lysate containing PCNA. After incubation at 30°C for 30 minutes in the presence of 1 mM ATP, proteins were immunoprecipitated from cell lysates with an anti-CDK2 antiserum. Immunoprecipitates were split for direct analysis of coimmunoprecipitated proteins or for kinase assays using histone H1 as a substrate.

(iv) *p21 inhibits cyclin D1/CDK4 kinase*

Lysates from Sf9 cells co-infected with baculoviruses encoding cyclin D1 and CDK4 were incubated with increasing amounts of a p21-containing lysate at 30°C for 30 minutes. Lysates from cells infected with baculoviruses encoding either cyclin D1 or CDK4 were split for analysis of proteins immunoprecipitated with an anti-cyclin D1 antiserum or for kinase assays using recombinant retinoblastoma protein (GST-RB) as the substrate. Briefly, for preparation of kinase extracts, cells were rinsed once with phosphate-buffered saline (PBS) and once with kinase buffer (50 mM Tris, pH7.4, 10 mM MgCl<sub>2</sub>, 5 mM EGTA, and 2 mM DTT). Cells were then lysed in kinase buffer by four passages through a 25 gauge needle. The cell lysates were cleared of insoluble material by two centrifugations at 12,999 xg and stored at -80°C until use. For cyclin D1/CDK4 complexes, the lysates were from cells co-infected with baculoviruses encoding cyclin D1 and CDK4. In certain preparations, lysates containing either cyclin A, CDK2, p21 or PCNA were mixed in the presence of 1 mM ATP for 30 minutes at 30°C. In all experiments, differences in reaction volumes were compensated with lysates from Sf9 cells infected with wild type baculovirus. After incubation, the reactions were stopped by adding 20 mM EDTA and the cyclin/CDK protein complexes were immunoprecipitated. After immunoprecipitation, the samples were split in half; half was used for the analysis of the protein composition and half for kinase assay. Histone H1 kinase assays were performed as described (Draetta et al., *Cell* 54: 17-26 (1988)). For the analysis of cyclin D1/CDK4 kinase activity, lysates were incubated at 30°C for 30 minutes without ATP and kinase activity was assayed using bacterially produced retinoblastoma fusion protein (GST-RB) as described (Ewen et al., *Cell* 73: 487-497 (1993)).

(v) *Colony formation suppression assay*

SAOS-2 cells were transfected with either a control plasmid (pRC-CMV) a plasmid directing the overexpression of human p53 (pCMBp53) or one of two independent preparations of a plasmid directing the expression of p21 (pRC-CMVp21). Stable transfectants were selected on the basis of resistance to G418. Colonies are visualized by staining with crystal violet.

The abundance of the p21 mRNA was observed to increase by treatment with ionizing radiation. Human lymphocytes (HL-60) were irradiated with 5 Gray of  $\gamma$ -radiation. Four hours after treatment, RNA was prepared from these and from unrelated controls (ML-1). This RNA was used for northern blotting with a probe derived from the p21 cDNA. The amount of RNA loaded in each lane was standardized by over-probing the blot with a probe specific for human  $\beta$ -actin. Quantitation on a Fuji BAS2000 bio-imager revealed that irradiation of ML-1 cells increased p21 mRNA abundance by 9.9 fold, whereas treatment of HL-60 failed to produce a significant change.

p21 mRNA is reduced in fibroblasts from p53 "knockout" mice. RNA was prepared from normal mouse embryo fibroblasts (p53+/+) or fibroblasts from a mouse embryo harboring a homozygous deletion of p53 (p53 -/-). This was used for northern blotting with a probe consisting of the murine p21 cDNA. Quantitation revealed an approximately 50-fold decrease in p21 message levels in the p53 -/- cells. For colony formation assays, SAOS-2 cells were transfected using lipofectamine (BRL) according to the manufacturers instructions (3  $\mu$ g DNA and 10  $\mu$ l of lipofectamine per 35 mm plate). At 48 hours post transfection, cells were split 1:10 into DMEM (Gibco) supplemented with 10% fetal bovine serum and 300 $\mu$ g/ml G418 (Gibco). Media was changed at 1 week intervals for three weeks after which cell were fixed and stained with crystal violet as described (Zhu et al., *Genes Dev.* 7: 1111-1125 (1992)). RNA was prepared using RNazol B according to the manufacturers instructions. Preparation of probes and northern blotting was as described (*Molecular Cloning: A Laboratory Manual 2ed*, eds. Sambrook et al., CSH Laboratory Press: 1989). Cells were cultured as described (Kastan et al., *Cell* 71: 587-597 (1992)). The murine p21 cDNA was isolated by hybridization with the human p21 cDNA. Mouse and human p21 proteins were found to share approximately 60% amino acid identity.

All of the above-cited references and publications are hereby incorporated by reference.

*EQUIVALENTS*

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention  
5 described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT: Beach, David  
Xiong, Yue

10

(ii) TITLE OF INVENTION: Cyclin Complex Rearrangement and Uses  
Related Thereto

(iii) NUMBER OF SEQUENCES: 6

15

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: LAHIVE & COCKFIELD  
(B) STREET: 60 State Street  
(C) CITY: Boston  
(D) STATE: MA  
(E) COUNTRY: USA  
(F) ZIP: 02109

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: ASCII(text)

25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US  
(B) FILING DATE: 19-NOV-1993  
(C) CLASSIFICATION:

30

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/991,997  
(B) FILING DATE: 17-DEC-1993

35

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/963,308  
(B) FILING DATE: 16-OCT-1993

40

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/888,178  
(B) FILING DATE: 26-MAY-1993

45

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/701,514  
(B) FILING DATE: 16-MAY-1993

50

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Vincent, Matthew P.  
(B) REGISTRATION NUMBER: 36,709  
(C) REFERENCE/DOCKET NUMBER: MII-026

55

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 227-7400

*Cancelled  
per Amst. I*

(B) TELEFAX: (617) 227-5941

(2) INFORMATION FOR SEQ ID NO:1:

5 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1089 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:  
 15 (A) NAME/KEY: CDS  
 (B) LOCATION: 13..888

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

20 CCGGCCGCCG CG ATG CAG AAA TAC GAG AAA CTG GAA AAG ATT GGG GAA 48  
 Met Gln Lys Tyr Glu Lys Leu Glu Lys Ile Gly Glu  
 1 5 10

25 GGC ACC TAC GGA ACT GTG TTC AAG GCC AAA AAC CGG GAG ACT CAT GAG 96  
 Gly Thr Tyr Gly Thr Val Phe Lys Ala Lys Asn Arg Glu Thr His Glu  
 15 20 25

30 ATC GTG GCT CTA AAA CGG GTG AGG CTG GAT GAC GAT GAT GAG GGT GTG 144  
 Ile Val Ala Leu Lys Arg Val Arg Leu Asp Asp Asp Asp Glu Gly Val  
 30 35 40

35 CCG AGT TCC GCC CTC CGG GAG ATC TGC CTA CTC AAG GAG CTG AAG CAC 192  
 Pro Ser Ser Ala Leu Arg Glu Ile Cys Leu Leu Lys Glu Leu Lys His  
 45 50 55 60

40 AAG AAC ATC GTC AGG CTT CAT GAC GTC CTG CAC AGC GAC AAG AAG CTG 240  
 Lys Asn Ile Val Arg Leu His Asp Val Leu His Ser Asp Lys Lys Leu  
 65 70 75

45 ACT TTG GTT TTT GAA TTC TGT GAC CAG GAC CTG AAG AAG TAT TTT GAC 288  
 Thr Leu Val Phe Glu Phe Cys Asp Gln Asp Leu Lys Lys Tyr Phe Asp  
 80 85 90

50 AGT TGC AAT GGT GAC CTC GAT CCT GAG ATT GTA AAG TCA TTC CTC TTC 336  
 Ser Cys Asn Gly Asp Leu Asp Pro Glu Ile Val Lys Ser Phe Leu Phe  
 95 100 105

CAG CTA CTA AAA GGG CTG GGA TTC TGT CAT AGC CGC AAT GTG CTA CAC 384  
 Gln Leu Leu Lys Gly Leu Gly Phe Cys His Ser Arg Asn Val Leu His  
 110 115 120

AGG GAC CTG AAG CCC CAG AAC CTG CTA ATA AAC AGG AAT GGG GAG CTG 432  
 Arg Asp Leu Lys Pro Gln Asn Leu Leu Ile Asn Arg Asn Gly Glu Leu

	125		130		135		140	
	AAA TTG GCT GAT TTT GGC CTG GCT CGA GCC TTT GGG ATT CCC GTC CGC	480						
5	Lys Leu Ala Asp Phe Gly Leu Ala Arg Ala Phe Gly Ile Pro Val Arg							
	145 150 155							
	TGT TAC TCA GCT GAG GTG GTC ACA CTG TGG TAC CGC CCA CCG GAT GTC	528						
	Cys Tyr Ser Ala Glu Val Val Thr Leu Trp Tyr Arg Pro Pro Asp Val							
	160 165 170							
10	CTC TTT GGG GCC AAG CTG TAC TCC ACG TCC ATC GAC ATG TGG TCA GCC	576						
	Leu Phe Gly Ala Lys Leu Tyr Ser Thr Ser Ile Asp Met Trp Ser Ala							
	175 180 185							
15	GGC TGC ATC TTT GCA GAG CTG GCC AAT GCT GGG CGG CCT CTT TTT CCC	624						
	Gly Cys Ile Phe Ala Glu Leu Ala Asn Ala Gly Arg Pro Leu Phe Pro							
	190 195 200							
20	GGC AAT GAT GTC GAT GAC CAG TTG AAG AGG ATC TTC CGA CTG CTG GGG	672						
	Gly Asn Asp Val Asp Asp Gln Leu Lys Arg Ile Phe Arg Leu Leu Gly							
	205 210 215 220							
	ACG CCC ACC GAG GAG CAG TGG CCC TCT ATC ACC AAG CTG CCA GAC TAT	720						
25	Thr Pro Thr Glu Glu Gln Trp Pro Ser Met Thr Lys Leu Pro Asp Tyr							
	225 230 235							
	AAG CCC TAT CCG ATG TAC CCG GCC ACA ACA TCC CTG GTG AAC GTC GTG	768						
	Lys Pro Tyr Pro Met Tyr Pro Ala Thr Thr Ser Leu Val Asn Val Val							
	240 245 250							
30	CCC AAA CTC AAT GCC ACA GGG AGG GAT CTG CTG CAG AAC CTT CTG AAG	816						
	Pro Lys Leu Asn Ala Thr Gly Arg Asp Leu Leu Gln Asn Leu Leu Lys							
	255 260 265							
35	TGT AAC CCT GTC CAG CGT ATC TCA GCA GAA GAG GCC CTG CAG CAC CCC	864						
	Cys Asn Pro Val Gln Arg Ile Ser Ala Glu Glu Ala Leu Gln His Pro							
	270 275 280							
40	TAC TTC TCC GAC TTC TGT CCG CCC TAGGCCCCGGG ACCCCCGGCC TCAGCTGGGC	918						
	Tyr Phe Ser Asp Phe Cys Pro Pro							
	285 290							
	CTGGCCTATT TAAGCCCCTC TTGAGAGGGG TGAGACAGTG GGGGTGCCTG GTGCGCTGTG	978						
45	CTCAGCAGTG CTGGGCCAGC CGGGGTGGGG TGCCTGAGCC CGAATTTC TC ACTCCCTTTG	1038						
	TGGA CTTTAT TTAATTTTCAT AAATTGGCTC CTTTCCACAAAAAAG G	1089						

50 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid



(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

	Met	Gln	Lys	Tyr	Glu	Lys	Leu	Glu	Lys	Ile	Gly	Glu	Gly	Thr	Tyr	Gly	
	1				5					10					15		
10	Thr	Val	Phe	Lys	Ala	Lys	Asn	Arg	Glu	Thr	His	Glu	Ile	Val	Ala	Leu	
				20					25					30			
	Lys	Arg	Val	Arg	Leu	Asp	Asp	Asp	Asp	Glu	Gly	Val	Pro	Ser	Ser	Ala	
				35				40					45				
15	Leu	Arg	Glu	Ile	Cys	Leu	Leu	Lys	Glu	Leu	Lys	His	Lys	Asn	Ile	Val	
		50					55					60					
	Arg	Leu	His	Asp	Val	Leu	His	Ser	Asp	Lys	Lys	Leu	Thr	Leu	Val	Phe	
20		65					70				75					80	
	Glu	Phe	Cys	Asp	Gln	Asp	Leu	Lys	Lys	Tyr	Phe	Asp	Ser	Cys	Asn	Gly	
					85					90					95		
25	Asp	Leu	Asp	Pro	Glu	Ile	Val	Lys	Ser	Phe	Leu	Phe	Gln	Leu	Leu	Lys	
				100					105					110			
	Gly	Leu	Gly	Phe	Cys	His	Ser	Arg	Asn	Val	Leu	His	Arg	Asp	Leu	Lys	
			115					120					125				
30	Pro	Gln	Asn	Leu	Leu	Ile	Asn	Arg	Asn	Gly	Glu	Leu	Lys	Leu	Ala	Asp	
			130				135						140				
	Phe	Gly	Leu	Ala	Arg	Ala	Phe	Gly	Ile	Pro	Val	Arg	Cys	Tyr	Ser	Ala	
35		145				150				155					160		
	Glu	Val	Val	Thr	Leu	Trp	Tyr	Arg	Pro	Pro	Asp	Val	Leu	Phe	Gly	Ala	
					165					170					175		
40	Lys	Leu	Tyr	Ser	Thr	Ser	Ile	Asp	Met	Trp	Ser	Ala	Gly	Cys	Ile	Phe	
				180					185					190			
	Ala	Glu	Leu	Ala	Asn	Ala	Gly	Arg	Pro	Leu	Phe	Pro	Gly	Asn	Asp	Val	
			195					200					205				
45	Asp	Asp	Gln	Leu	Lys	Arg	Ile	Phe	Arg	Leu	Leu	Gly	Thr	Pro	Thr	Glu	
			210				215					220					
	Glu	Gln	Trp	Pro	Ser	Met	Thr	Lys	Leu	Pro	Asp	Tyr	Lys	Pro	Tyr	Pro	
50						230					235				240		
	Met	Tyr	Pro	Ala	Thr	Thr	Ser	Leu	Val	Asn	Val	Val	Pro	Lys	Leu	Asn	
					245					250					255		

Ala Thr Gly Arg Asp Leu Leu Gln Asn Leu Leu Lys Cys Asn Pro Val  
260 265 270

5 Gln Arg Ile Ser Ala Glu Glu Ala Leu Gln His Pro Tyr Phe Ser Asp  
275 280 285

Phe Cys Pro Pro  
290

10

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 948 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(ix) FEATURE:

25

- (A) NAME/KEY: CDS
- (B) LOCATION: 19..465

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

30 AATTCGGCAC GAGGCAGC ATG GAG CCT TCG GCT GAC TGG CTG GCC ACG GCC 51  
Met Glu Pro Ser Ala Asp Trp Leu Ala Thr Ala  
1 5 10

35 GCG GCC CGG GGT CGG GTA GAG GAG GTG CGG GCG CTG CTG GAG GCG GTG 99  
Ala Ala Arg Gly Arg Val Glu Glu Val Arg Ala Leu Leu Glu Ala Val  
15 20 25

40 GCG CTG CCC AAC GCA CCG AAT AGT TAC GGT CGG AGG CCG ATC CAG GTC 147  
Ala Leu Pro Asn Ala Pro Asn Ser Tyr Gly Arg Arg Pro Ile Gln Val  
30 35 40

45 ATG ATG ATG GGC AGC GCC CGA GTG GCG GAG CTG CTG CTG CTC CAC GGC 195  
Met Met Met Gly Ser Ala Arg Val Ala Glu Leu Leu Leu Leu His Gly  
45 50 55

50 GCG GAG CCC AAC TGC GCC GAC CCC GCC ACT CTC ACC CGA CCC GTG CAC 243  
Ala Glu Pro Asn Cys Ala Asp Pro Ala Thr Leu Thr Arg Pro Val His  
60 65 70 75

50 GAC GCT GCC CGG GAG GGC TTC CTG GAC ACG CTG GTG GTG CTG CAC CGG 291  
Asp Ala Ala Arg Glu Gly Phe Leu Asp Thr Leu Val Val Leu His Arg  
80 85 90

GCC GGG GCG CGG CTG GAC GTG CGC GAT GCC TGG GGC CGT CTG CCC GTG 339  
Ala Gly Ala Arg Leu Asp Val Arg Asp Ala Trp Gly Arg Leu Pro Val

	95	100	105	
	GAC CTG GCT GAG GAG CTG GGC CAT CGC GAT GTC GCA CGG TAC CTG CGC			387
5	Asp Leu Ala Glu Glu Leu Gly His Arg Asp Val Ala Arg Tyr Leu Arg			
	110	115	120	
	GCG GCT GCG GGG GGC ACC AGA GGC AGT AAC CAT GCC CGC ATA GAT GCC			435
	Ala Ala Ala Gly Gly Thr Arg Gly Ser Asn His Ala Arg Ile Asp Ala			
	125	130	135	
10	GCG GAA GGT CCC TCA GAC ATC CCC GAT TGAAAGAACC AGAGAGGCTC			482
	Ala Glu Gly Pro Ser Asp Ile Pro Asp			
	140	145		
15	TGAGAAACCT CGGGAAACTT AGATCATCAG TCACCGAAGG TCCTACAGGG CCACAACGTC			542
	CCCCGCCACA ACCCACCCTG CTTTCGTAGT TTTCATTTAG AAAATAGAGC TTTTAAAAAT			602
	GTCCTGCCTT TTAACGTAGA TATAAGCCTT CCCCCTACTAC CGTAAATGTC CATTTATATC			662
20	ATTTTTTATA TATTCTTATA AAAATGTAAA AAAGAAAAAC ACCGCTTCTG CCTTTTCACT			722
	GTGTTGGAGT TTTCTGGAGT GAGCACTCAC GCCCTAAGCG CACATTCATG TGGGCATTTT			782
25	TTGCGAGCCT CGCAGCCTCC GGAAGCTGTC GACTTCATGA CAAGCATTTT GTGAACTAGG			842
	GAAGCTCAGG GGGGTTACTG GCTTCTCTTG AGTCACACTG CTAGCAAATG GCAGAACCAA			902
	AGCTCAAATA AAAATAAAAT TATTTTCATT CATTCACTCA AAAAAA			948
30				

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 148 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Glu Pro Ser Ala Asp Trp Leu Ala Thr Ala Ala Ala Arg Gly Arg	
1 5 10 15	
Val Glu Glu Val Arg Ala Leu Leu Glu Ala Val Ala Leu Pro Asn Ala	
20 25 30	
Pro Asn Ser Tyr Gly Arg Arg Pro Ile Gln Val Met Met Met Gly Ser	
35 40 45	
Ala Arg Val Ala Glu Leu Leu Leu Leu His Gly Ala Glu Pro Asn Cys	
50 55 60	

Ala Asp Pro Ala Thr Leu Thr Arg Pro Val His Asp Ala Ala Arg Glu  
65 70 75 80

5 Gly Phe Leu Asp Thr Leu Val Val Leu His Arg Ala Gly Ala Arg Leu  
85 90 95

Asp Val Arg Asp Ala Trp Gly Arg Leu Pro Val Asp Leu Ala Glu Glu  
100 105 110

10 Leu Gly His Arg Asp Val Ala Arg Tyr Leu Arg Ala Ala Ala Gly Gly  
115 120 125

Thr Arg Gly Ser Asn His Ala Arg Ile Asp Ala Ala Glu Gly Pro Ser  
130 135 140

15 Asp Ile Pro Asp  
145

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2100 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 79..573

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCTGCCGAAG TCAGTTCCTT GTGGAGCCGG AGCTGGGCGC GGATTCGCCG AGGCACCGAG 60

40 GCACTCAGAG GAGGCGCC ATG TCA GAA CCG CGT GGG GAT GTC CGT CAG AAC 111  
Met Ser Glu Pro Arg Gly Asp Val Arg Gln Asn  
1 5 10

CCA TGC GGC AGC AAG GCC TGC CGC CGC CTC TTC GGC CCA GTG GAC AGC 159  
45 Pro Cys Gly Ser Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser  
15 20 25

GAG CAG CTG AGC CGC GAC TGT GAT GCG CTA ATG GCG GGC TGC ATC CAG 207  
50 Glu Gln Leu Ser Arg Asp Cys Asp Ala Leu Met Ala Gly Cys Ile Gln  
30 35 40

GAG GCC CGT GAG CGA TGG AAC TTC GAC TTT GTC ACC GAG ACA CCA CTG 255  
Glu Ala Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu  
45 50 55

	GAG GGT GAC TTC GCC TGG GAG CGT GTG CGG GGC CTT GGC CTG CCC AAG	303
	Glu Gly Asp Phe Ala Trp Glu Arg Val Arg Gly Leu Gly Leu Pro Lys	
	60 65 70 75	
5	CTC TAC CTT CCC ACG GGG CCC CGG CGA GGC CGG GAT GAG TTG GGA GGA	351
	Leu Tyr Leu Pro Thr Gly Pro Arg Arg Gly Arg Asp Glu Leu Gly Gly	
	80 85 90	
10	GGC AGG CGG CCT GGC ACC TCA CCT GCT CTG CTG CAG GGG ACA GCA GAG	399
	Gly Arg Arg Pro Gly Thr Ser Pro Ala Leu Leu Gln Gly Thr Ala Glu	
	95 100 105	
15	GAA GAC CAT GTG GAC CTG TCA CTG TCT TGT ACC CTT GTG CCT CGT TCA	447
	Glu Asp His Val Asp Leu Ser Leu Ser Cys Thr Leu Val Pro Arg Ser	
	110 115 120	
20	GGG GAG CAG GCT GAA GGG TCC CCA GGT GGA CCT GGA GAC TCT CAG GGT	495
	Gly Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly	
	125 130 135	
25	CGA AAA CGG CGG CAG ACC AGC ATG ACA GAT TTC TAC CAC TCC AAA CGC	543
	Arg Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg	
	140 145 150 155	
30	CGG CTG ATC TTC TCC AAG AGG AAG CCC TAATCCGCCC ACAGGAAGCC	590
	Arg Leu Ile Phe Ser Lys Arg Lys Pro	
	160 165	
35	TGCAGTCCTG GAAGCGCGAG GGCCTCAAAG GCCCCTCTA CACCTTCTGC CTTAGTCTCA	650
	GTTTGTGTGT CTTAATTATT ATTTGTGTTT TAATTTAAAC ACCTCCTCAT GTACATACCC	710
	TGGCCGCCCC CTGCCCCCA GCCTCTGGCA TTAGAATTAT TTAAACAAAA ACTAGGCGGT	770
40	TGAATGAGAG GTTCCTAAGA GTGCTGGGCA TTTTATTTT ATGAAATACT ATTTAAAGCC	830
	TCCTCATCCC GTGTTCTCCT TTCCTCTCT CCCGGAGGTT GGGTGGGCG GCTTCATGCC	890
45	AGCTACTTCC TCCTCCCCAC TTGTCCGCTG GGTGGTACCC TCTGGAGGGG TGTGGCTCCT	950
	TCCCATCGCT GTCACAGGCG GTTATGAAAT TCACCCCTT TCCTGGACAC TCAGACCTGA	1010
	ATTCTTTTTC ATTTGAGAAG TAAACAGATG GGACTTTGAA GGGGCCTCAC CGAGTGGGGG	1070
	CATCATCAAA AACTTTGGAG TCCCCTCACC TCCTCTAAGG TTGGGCAGGG TGACCCTGAA	1130
	GTGAGCACAG CCTAGGGCTG AGCTGGGGAC CTGGTACCCT CCTGGCTCTT GATACCCCCC	1190
50	TCTGTCTTGT GAAGGCAGGG GGAAGGTGGG GTCCTGGAGC AGACCACCCC GCCTGCCCTC	1250
	ATGGCCCCTC TGACCTGCAC TGGGGAGCCC GTCTCAGTGT TGAGCCTTTT CCCTCTTTGG	1310
	CTCCCCTGTA CCTTTTGAGG AGCCCCAGCT ACCCTTCTTC TCCAGCTGGG CTCTGCAATT	1370

5  
 10  
 15  
 20  
 25

CCCCTCTGCT GCTGTCCCTC CCCCTTGTCC TTTCCCTTCA GTACCCTCTC AGCTCCAGGT 1430  
 GGCTCTGAGG TGCCTGTCCC ACCCCCACCC CCAGCTCAAT GGACTGGAAG GGGAAGGGAC 1490  
 ACACAAGAAG AAGGGCACCC TAGTTCTACC TCAGGCAGCT CAAGCAGCGA CCGCCCCCTC 1550  
 CTCTAGCTGT GGGGGTGAGG GTCCCATGTG GTGGCACAGG CCCCCTTGAG TGGGGTTATC 1610  
 TCTGTGTTAG GGGTATATGA TGGGGGAGTA GATCTTTCTA GGAGGGAGAC ACTGGCCCCT 1670  
 CAAATCGTCC AGCGACCTTC CTCATCCACC CCATCCCTCC CCAGTTCATT GCACTTTGAT 1730  
 TAGCAGCGGA ACAAGGAGTC AGACATTTTA AGATGGTGGC AGTAGAGGCT ATGGACAGGG 1790  
 CATGCCACGT GGGCTCATAT GGGGCTGGGA GTAGTTGTCT TTCCTGGCAC TAAGCTTGAG 1850  
 CCCCTGGAGG CACTGAAGTG CTTAGTGTAC TTGGAGTATT GGGGTCTGAC CCCAAACACC 1910  
 TTCCAGCTCC TGTAACATAC TGGCCTGGAC TGTTTTCTCT CGGCTCCCCA TGTGTCCTGG 1970  
 TTCCCGTTTC TCCACCTAGA CTGTAAACCT CTCGAGGGCA GGGACCACAC CCTGTACTGT 2030  
 TCTGTGTCTT TCACAGCTCC TCCCACAATG CTGATATACA GCAGGTGCTC AATAAACGAT 2090  
 TCTTAGTGAA 2100

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 164 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

40 Met Ser Glu Pro Arg Gly Asp Val Arg Gln Asn Pro Cys Gly Ser Lys  
 1 5 10 15  
 Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser Arg  
 20 25 30  
 45 Asp Cys Asp Ala Leu Met Ala Gly Cys Ile Gln Glu Ala Arg Glu Arg  
 35 40 45  
 Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly Asp Phe Ala  
 50 55 60  
 Trp Glu Arg Val Arg Gly Leu Gly Leu Pro Lys Leu Tyr Leu Pro Thr  
 65 70 75 80

Gly Pro Arg Arg Gly Arg Asp Glu Leu Gly Gly Gly Arg Arg Pro Gly  
85 90 95

5 Thr Ser Pro Ala Leu Leu Gln Gly Thr Ala Glu Glu Asp His Val Asp  
100 105 110

Leu Ser Leu Ser Cys Thr Leu Val Pro Arg Ser Gly Glu Gln Ala Glu  
115 120 125

10 Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln  
130 135 140

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser  
145 150 155 160

15 Lys Arg Lys Pro

1. A method of diagnosing transformation of a cell, comprising determining whether p21 is:
  - a) complexed with a cyclin kinase, a cyclin, or both, or
  - b) not complexed with a cyclin kinase, a cyclin, or both,wherein if p21 is not complexed with a cyclin kinase, a cyclin, or both, it is indicative of transformation of the cell.
2. A method of Claim 1, wherein an antibody is used to determine whether or not p21 is complexed with a cyclin kinase, a cyclin, or both.
3. A method of Claim 1, wherein the cyclin is a D-type cyclin or an A-type cyclin and the cyclin kinase is CDK4.
4. A method of diagnosing transformation of a cell, comprising determining whether p16 is
  - a) complexed with a cyclin kinase, or
  - b) not complexed with a cyclin kinase,wherein if p16 is complexed with a cyclin kinase, it is indicative of transformation of the cell.
5. A method of Claim 4, wherein an antibody is used to determine whether or not p16 is complexed with a cyclin kinase.
6. A method of Claim 4, wherein the cyclin kinase is CDK4.
7. A method of diagnosing transformation of a cell, comprising determining whether p19 is
  - a) complexed with a cyclin, or
  - b) not complexed with a cyclin, wherein p19 is complexed with a cyclin, it is indicative of transformation of the cell.
8. A method of Claim 7, wherein an antibody is used to determine whether or not p19 is complexed with a cyclin.
9. A method of Claim 7, wherein the cyclin is cyclin A.



10. Recombinant CDK5 having the amino acid sequence of SEQ ID No. 2.
11. cDNA encoding CDK5.
- 5 12. Isolated DNA having the nucleotide sequence of SEQ ID No. 1.
13. Recombinant p16<sup>INK4</sup> having the amino acid sequence of SEQ ID No. 4
- 10 14. cDNA encoding p16<sup>INK4</sup>.
- 15 15. Isolated DNA having the nucleotide sequence of SEQ ID No. 3.
16. A diagnostic test kit for identifying transformed cells, comprising an antibody specific for p16<sup>ink4</sup> for measuring, in a sample of cells isolated from a patient, a level of cells displaying an increased level of a p16 protein.
17. The diagnostic kit of claim 16, wherein the p16<sup>ink4</sup> specific antibody is specific for a protein having an amino acid sequence of SEQ ID No. 4.
- 20 18. A diagnostic test kit for identifying an transformed cells, comprising an nucleic acid probe, specific for p16<sup>ink4</sup> nucleic sequences, for measuring, in a sample of cells isolated from a patient, a level of cells displaying an increased level of a p16 mRNA.
- 25 19. The diagnostic test kit of claim 18, wherein the nucleic acid probe is derived from a nucleic acid sequence of SEQ ID NO. 3.

20. An assay for identifying an inhibitor of a cyclin-dependent kinase, comprising
- i. providing a cdk-complex comprising a cyclin, a cyclin-dependent kinase (cdk), and p21, wherein the cdk-complex is isolated substantially free of other proteins normally present with the cdk-complex in a cell in which the cdk-complex naturally occurs;
  - ii. contacting the cdk-complex with a substrate which the cdk-complex can phosphorylate, and with a candidate inhibitor;
  - iii. measuring a level of phosphorylation of the substrate; and
  - iv. comparing the level of phosphorylation of the substrate in the presence of the candidate inhibitor to a level of phosphorylation of the substrate in the absence of the candidate inhibitor,
- wherein a decrease in the level of phosphorylation in the presence of the candidate inhibitor is indicative of a cdk inhibitory activity of the candidate inhibitor.
21. An assay for identifying an inhibitor of a cyclin-dependent kinase, which inhibitor selectively able to inhibit proliferation of a transformed cell having relative to proliferation of a normal cell, comprising
- i. providing
    - a first cdk-complex derived from the normal cell comprising a cyclin, a cyclin-dependent kinase (cdk), and p21, and
    - a second cdk-complex derived from the transformed cell comprising the cyclin and the cdk,wherein each of the first and second cdk-complexes are isolated substantially free of other proteins normally present with the cdk-complex in the cell in which the cdk-complex is derived;
  - ii. contacting each of the cdk-complexes with a substrate which the cdk-complex can phosphorylate, and with a candidate inhibitor;
  - iii. measuring a level of phosphorylation of the substrate; and
  - iv. comparing, for each of the cdk-complexes, the level of phosphorylation of the substrate in the presence of the candidate inhibitor to a level of phosphorylation of the substrate in the absence of the candidate inhibitor,
- wherein a decrease in the level of phosphorylation in the presence of the candidate inhibitor is indicative of a cdk inhibitory activity of the candidate inhibitor, and the selectivity of the inhibitor being determined by comparing the difference of cdk inhibitory activity between the first and second cdk-complex.

*Abstract of the Disclosure*

- 5        A method and diagnostic kit for diagnosing transformation of a cell, involving detection of the subunit components of cyclin complexes, is disclosed. In particular, the method pertains to the interaction of cyclins, PCNA, CDKs, and low molecular weight polypeptides such as p21, p19 and p16. The invention further pertains to inhibitors of cell proliferation.